array:23 [
  "pii" => "S2666275222001849"
  "issn" => "26662752"
  "doi" => "10.1016/j.abdp.2022.07.027"
  "estado" => "S300"
  "fechaPublicacion" => "2022-09-01"
  "aid" => "600"
  "copyrightAnyo" => "2022"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by/4.0/"
  "subdocumento" => "fla"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:18 [
      "pii" => "S0365059622001386"
      "issn" => "03650596"
      "doi" => "10.1016/j.abd.2022.03.003"
      "estado" => "S300"
      "fechaPublicacion" => "2022-09-01"
      "aid" => "600"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by/4.0/"
      "subdocumento" => "fla"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
        "titulo" => "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria&#58; can we define better-responding endotypes&#63;"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "592"
            "paginaFinal" => "600"
          ]
        ]
        "contieneResumen" => array:1 [
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig0005"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1672
                "Ancho" => 1675
                "Tamanyo" => 199167
              ]
            ]
            "detalles" => array:1 [
              0 => array:3 [
                "identificador" => "at0005"
                "detalle" => "Figure "
                "rol" => "short"
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The distribution of four types of treatment responses&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Emek Kocat&#252;rk, Emel B&#252;lb&#252;l Ba&#351;kan, &#214;zlem Su K&#252;&#231;&#252;k, Mustafa &#214;zdemir, Sinem &#214;rnek, Pelin Kuteyla Can, Eda Ha&#351;al, Burhan Engin, Nilg&#252;n Atakan, Erkan Alpsoy"
            "autores" => array:10 [
              0 => array:2 [
                "nombre" => "Emek"
                "apellidos" => "Kocat&#252;rk"
              ]
              1 => array:2 [
                "nombre" => "Emel B&#252;lb&#252;l"
                "apellidos" => "Ba&#351;kan"
              ]
              2 => array:2 [
                "nombre" => "&#214;zlem Su"
                "apellidos" => "K&#252;&#231;&#252;k"
              ]
              3 => array:2 [
                "nombre" => "Mustafa"
                "apellidos" => "&#214;zdemir"
              ]
              4 => array:2 [
                "nombre" => "Sinem"
                "apellidos" => "&#214;rnek"
              ]
              5 => array:2 [
                "nombre" => "Pelin Kuteyla"
                "apellidos" => "Can"
              ]
              6 => array:2 [
                "nombre" => "Eda"
                "apellidos" => "Ha&#351;al"
              ]
              7 => array:2 [
                "nombre" => "Burhan"
                "apellidos" => "Engin"
              ]
              8 => array:2 [
                "nombre" => "Nilg&#252;n"
                "apellidos" => "Atakan"
              ]
              9 => array:2 [
                "nombre" => "Erkan"
                "apellidos" => "Alpsoy"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "pt" => array:9 [
          "pii" => "S2666275222001849"
          "doi" => "10.1016/j.abdp.2022.07.027"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "pt"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001849?idApp=UINPBA00008Z"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622001386?idApp=UINPBA00008Z"
      "url" => "/03650596/0000009700000005/v1_202208290604/S0365059622001386/v1_202208290604/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2666275222001412"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2022.07.004"
    "estado" => "S300"
    "fechaPublicacion" => "2022-09-01"
    "aid" => "574"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Artigo original</span>"
      "titulo" => "Fatores preditivos da espessura do melanoma"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "tieneResumen" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "601"
          "paginaFinal" => "605"
        ]
      ]
      "contieneResumen" => array:1 [
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Rita Carreiro Silva, Ricardo Jos&#233; David Costa Vieira"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Ana Rita Carreiro"
              "apellidos" => "Silva"
            ]
            1 => array:2 [
              "nombre" => "Ricardo Jos&#233; David Costa"
              "apellidos" => "Vieira"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S036505962200112X"
        "doi" => "10.1016/j.abd.2021.12.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S036505962200112X?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001412?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009700000005/v1_202209080628/S2666275222001412/v1_202209080628/pt/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2666275222001552"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2022.07.017"
    "estado" => "S300"
    "fechaPublicacion" => "2022-09-01"
    "aid" => "590"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Artigo original</span>"
      "titulo" => "O uso da t&#233;cnica de avalia&#231;&#227;o intraoperat&#243;ria de margens cir&#250;rgicas por congela&#231;&#227;o &#8220;<span class="elsevierStyleItalic">en face&#8221;</span> no manejo de carcinomas cut&#226;neos&#58; resultados oncol&#243;gicos de uma &#250;nica institui&#231;&#227;o"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "tieneResumen" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "583"
          "paginaFinal" => "591"
        ]
      ]
      "contieneResumen" => array:1 [
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1830
              "Ancho" => 2925
              "Tamanyo" => 377531
            ]
          ]
          "descripcion" => array:1 [
            "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Aspecto cl&#237;nico da les&#227;o antes da excis&#227;o com delimita&#231;&#227;o dermatosc&#243;pica das margens cir&#250;rgicas&#46; &#40;B&#41; Amostra ressecada e identificada com fio cir&#250;rgico pelo cirurgi&#227;o do ponto de refer&#234;ncia do paciente de 12 horas&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Carolina Vasconcellos Guedes Otsuka, Eduardo Bertolli, Mariana Petaccia de Macedo, Clovis Antonio Lopes Pinto, Jo&#227;o Pedreira Duprat Neto"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Ana Carolina Vasconcellos Guedes"
              "apellidos" => "Otsuka"
            ]
            1 => array:2 [
              "nombre" => "Eduardo"
              "apellidos" => "Bertolli"
            ]
            2 => array:2 [
              "nombre" => "Mariana Petaccia de"
              "apellidos" => "Macedo"
            ]
            3 => array:2 [
              "nombre" => "Clovis Antonio Lopes"
              "apellidos" => "Pinto"
            ]
            4 => array:2 [
              "nombre" => "Jo&#227;o Pedreira Duprat"
              "apellidos" => "Neto"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0365059622001283"
        "doi" => "10.1016/j.abd.2021.09.013"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622001283?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001552?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009700000005/v1_202209080628/S2666275222001552/v1_202209080628/pt/main.assets"
  ]
  "pt" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Artigo original</span>"
    "titulo" => "Omalizumabe <span class="elsevierStyleItalic">versus</span> ciclosporina&#8208;A para o tratamento da urtic&#225;ria cr&#244;nica espont&#226;nea&#58; podemos definir end&#243;tipos com melhor resposta&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "592"
        "paginaFinal" => "600"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Emek Kocat&#252;rk, Emel B&#252;lb&#252;l Ba&#351;kan, &#214;zlem Su K&#252;&#231;&#252;k, Mustafa &#214;zdemir, Sinem &#214;rnek, Pelin Kuteyla Can, Eda Ha&#351;al, Burhan Engin, Nilg&#252;n Atakan, Erkan Alpsoy"
        "autores" => array:10 [
          0 => array:4 [
            "nombre" => "Emek"
            "apellidos" => "Kocat&#252;rk"
            "email" => array:1 [
              0 => "ekocaturk@ku.edu.tr"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Emel B&#252;lb&#252;l"
            "apellidos" => "Ba&#351;kan"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "&#214;zlem Su"
            "apellidos" => "K&#252;&#231;&#252;k"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Mustafa"
            "apellidos" => "&#214;zdemir"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Sinem"
            "apellidos" => "&#214;rnek"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Pelin Kuteyla"
            "apellidos" => "Can"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Eda"
            "apellidos" => "Ha&#351;al"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Burhan"
            "apellidos" => "Engin"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Nilg&#252;n"
            "apellidos" => "Atakan"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Erkan"
            "apellidos" => "Alpsoy"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:9 [
          0 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Koc University&#44; Escola de Medicina&#44; Istambul&#44; Turquia"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Uludag University&#44; Escola de Medicina&#44; Bursa&#44; Turquia"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Bezmialem Vakif University&#44; Escola de Medicina&#44; Istambul&#44; Turquia"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Istanbul Medipol University&#44; Escola de Medicina&#44; Istambul&#44; Turquia"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Ankara Diskapi Yildirim Beyazit Training and Research Hospital&#44; Ankara&#44; Turquia"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; VM Medical Park Maltepe Hospital&#44; Istambul&#44; Turquia"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Istanbul University&#44; Escola de MedicinaCerrahpasa&#44; Istanbul&#44; Turquia"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Hacettepe University&#44; Escola de Medicina&#44; Ankara&#44; Turquia"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Akdeniz University&#44; Escola de Medicina&#44; Antalya&#44; Turquia"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspond&#234;ncia&#46;"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1672
            "Ancho" => 1675
            "Tamanyo" => 197262
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Distribui&#231;&#227;o dos quatro tipos de respostas ao tratamento da UCE&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Introdu&#231;&#227;o</span><p id="par0005" class="elsevierStylePara elsevierViewall">A urtic&#225;ria cr&#244;nica espont&#226;nea &#40;UCE&#41; &#233; definida como urticas e&#47;ou angioedema por mais de seis semanas&#46; A principal c&#233;lula efetora na fisiopatologia da doen&#231;a &#233; o mast&#243;cito&#44; que sofre degranula&#231;&#227;o ap&#243;s est&#237;mulo&#44; principalmente via Fc&#603;R1 de alta afinidade e leva &#224; libera&#231;&#227;o de v&#225;rios mediadores e resulta no recrutamento de c&#233;lulas como bas&#243;filos&#44; eosin&#243;filos e linf&#243;citos T&#46;<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">1&#44;2</span></a> &#201; amplamente aceito que mecanismos autoimunes desempenham papel importante na ativa&#231;&#227;o dos mast&#243;citos&#46; Na UCE&#44; postulam&#8208;se dois tipos de autoimunidade&#58; 1&#41; autoimunidade tipo I &#40;tamb&#233;m chamada de autoalergia&#41;&#44; na qual participam autoanticorpos IgE e 2&#41; autoimunidade tipo IIb&#44; na qual autoanticorpos IgG contra autoant&#237;genos ativam receptores de mast&#243;citos&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">3</span></a> As <span class="elsevierStyleItalic">International Urticaria Guidelines</span> recomendam omalizumabe &#40;Oma&#41; como tratamento de primeira linha na UCE resistente aos anti&#8208;histam&#237;nicos &#40;pacientes que n&#227;o respondem a doses quatro vezes maiores de anti&#8208;histam&#237;nicos H1&#41;&#44; enquanto ciclosporina&#8208;A &#40;CsA&#41; &#233; recomendada para pacientes que apresentam falha no tratamento com Oma&#46; Embora esse algoritmo gradativo tenha sido adotado&#44; ele pode ser demorado&#44; caro e pode n&#227;o ser adequado para todos os pacientes com UCE&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">1</span></a> J&#225; houve tentativas de encontrar biomarcadores ou caracter&#237;sticas cl&#237;nicas que definam a resposta ao tratamento em pacientes com UCE&#44; e o teste de soro aut&#243;logo&#44; ensaio de libera&#231;&#227;o de histamina de bas&#243;filos &#40;BHRA&#41;&#44; n&#237;veis totais de IgE&#44; <span class="elsevierStyleSmallCaps">d</span>&#8208;d&#237;mero e PCR s&#227;o alguns dos biomarcadores que foram identificados como associados &#224; resposta ao tratamento com Oma ou CsA&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">4</span></a> Entretanto&#44; muitos dos estudos realizados para determinar biomarcadores concentraram&#8208;se em um determinado medicamento&#44; neste caso Oma ou CsA&#44; mas faltam estudos comparando respondedores ao Oma com respondedores &#224; CsA&#46; O objetivo do presente estudo foi determinar se caracter&#237;sticas espec&#237;ficas dos pacientes ou marcadores laboratoriais poderiam ser utilizados como indicadores de resposta ao Oma ou &#224; CsA em pacientes com UCE&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">M&#233;todos</span><p id="par0010" class="elsevierStylePara elsevierViewall">Foram analisados retrospectivamente os arquivos de pacientes de sete centros da Turquia &#40;Okmeydani Training and Research Hospital&#44; Istanbul&#59; Uludag University&#44; School of Medicine&#44; Bursa&#59; Bezmialem Vakif University&#44; School of Medicine&#44; Istanbul&#59; Istanbul Medipol University&#44; School of Medicine&#44; Istanbul&#59; Istanbul University&#44; Cerrahpasa School of Medicine&#44; Istanbul&#59; Hacettepe University&#44; School of Medicine&#44; Ankara&#59; Akdeniz University&#44; School of Medicine&#44; Antalya&#41; com experi&#234;ncia no tratamento de pacientes com UCE&#46; O diagn&#243;stico de UCE foi realizado com base no exame f&#237;sico e na hist&#243;ria do paciente&#46; Os pacientes foram considerados resistentes aos anti&#8208;histam&#237;nicos quando n&#227;o responderam a doses quatro vezes maiores de anti&#8208;histam&#237;nicos H1&#46; Os crit&#233;rios de inclus&#227;o para pacientes com UCE foram&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1&#46;</span><p id="par0015" class="elsevierStylePara elsevierViewall">Ter UCE por mais de seis semanas&#59;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2&#46;</span><p id="par0020" class="elsevierStylePara elsevierViewall">Ser maior de 18 anos&#59;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3&#46;</span><p id="par0025" class="elsevierStylePara elsevierViewall">N&#227;o estar gr&#225;vida ou amamentando&#59;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4&#46;</span><p id="par0030" class="elsevierStylePara elsevierViewall">Ter sido submetido a uma tentativa de tratamento com Oma e CsA &#40;n&#227;o simultaneamente&#41; durante o curso da doen&#231;a por pelo menos tr&#234;s meses para decidir se houve resposta ao tratamento ou n&#227;o&#59;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5&#46;</span><p id="par0035" class="elsevierStylePara elsevierViewall">Incluir os escores do teste de controle de urtic&#225;ria &#40;UCT&#44; do ingl&#234;s <span class="elsevierStyleItalic">urticaria control test</span>&#41; e haver dados cl&#237;nicos e laboratoriais suficientes nos arquivos&#46;</p></li></ul></p><p id="par0040" class="elsevierStylePara elsevierViewall">Os crit&#233;rios de exclus&#227;o foram&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">1&#46;</span><p id="par0045" class="elsevierStylePara elsevierViewall">Urtic&#225;ria cr&#244;nica induzida&#59;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">2&#46;</span><p id="par0050" class="elsevierStylePara elsevierViewall">Pacientes menores de 18 anos&#59;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">3&#46;</span><p id="par0055" class="elsevierStylePara elsevierViewall">Tratamento com CsA e Oma simultaneamente&#46;</p></li></ul></p><p id="par0060" class="elsevierStylePara elsevierViewall">A resposta ao tratamento foi definida pelos escores do UCT &#40;UCT &#8805; 12&#44; sob controle&#41;&#46; Quatro grupos de pacientes foram definidos de acordo com as respostas ao tratamento&#58;<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">1&#46;</span><p id="par0065" class="elsevierStylePara elsevierViewall">Pacientes que respondem apenas ao Oma &#40;n&#227;o respondem &#224; CsA&#41; &#8211; Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">2&#46;</span><p id="par0070" class="elsevierStylePara elsevierViewall">Pacientes que respondem apenas &#224; CsA &#40;n&#227;o respondem ao Oma&#41; &#8211; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59;</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">3&#46;</span><p id="par0075" class="elsevierStylePara elsevierViewall">Pacientes que respondem ao Oma e &#224; CsA &#8211; Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">4&#46;</span><p id="par0080" class="elsevierStylePara elsevierViewall">Pacientes que n&#227;o respondem a nenhum dos medicamentos &#40;Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span>&#41;&#46;</p></li></ul></p><p id="par0085" class="elsevierStylePara elsevierViewall">Foi realizada compara&#231;&#227;o entre todos os grupos de resposta em rela&#231;&#227;o &#224;s caracter&#237;sticas como idade&#44; sexo&#44; hist&#243;ria familiar&#44; presen&#231;a de angioedema&#44; dura&#231;&#227;o da doen&#231;a&#44; urtic&#225;ria induzida &#40;UI&#41;&#44; escores UCT basais e marcadores laboratoriais&#44; como o teste cut&#226;neo com soro aut&#243;logo &#40;ASST&#44; <span class="elsevierStyleItalic">autologous serum skin test</span>&#41;&#44; n&#237;veis altos de PCR&#44; VHS&#44; eosinopenia&#44; basopenia&#44; n&#237;veis baixos de IgE total&#44; presen&#231;a de doen&#231;a autoimune da tireoide&#44; bem como positividade para anticorpo antiperoxidase tireoidiana &#40;anti&#8208;TPO&#41; e antitireoglobulina &#40;anti&#8208;TG&#41;&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">A aprova&#231;&#227;o &#233;tica foi obtida do Comit&#234; de &#201;tica do centro coordenador do Okmeydani Training and Research Hospital &#40;23&#47;05&#47;2017&#59; n&#250;mero 98&#8208;667&#41;&#46;</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Defini&#231;&#245;es</span><p id="par0095" class="elsevierStylePara elsevierViewall">Altos n&#237;veis de PCR&#58; &#8805; 5<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#59;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Altos n&#237;veis de VHS&#58; &#8805; 20<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#59;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Basopenia &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;01 &#215; 109&#47;L&#59;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Eosinopenia &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05 &#215; 109&#47;L&#59;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Baixos n&#237;veis de IgE total&#44; &#60;<span class="elsevierStyleHsp" style=""></span>43 UI&#47;mL&#59;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Doen&#231;a autoimune da tireoide &#40;AIT&#41;&#58; diagn&#243;stico estabelecido de AIT encontrado nos arquivos dos pacientes &#40;n&#227;o apenas da positividade ao anti&#8208;TPO&#47;anti&#8208;TG&#41;&#59;</p><p id="par0125" class="elsevierStylePara elsevierViewall">Alta atividade de doen&#231;a UCT &#60;<span class="elsevierStyleHsp" style=""></span>6&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">An&#225;lise estat&#237;stica</span><p id="par0130" class="elsevierStylePara elsevierViewall">As caracter&#237;sticas basais foram descritas como m&#233;dias e desvios&#8208;padr&#227;o &#40;DP&#41; para vari&#225;veis cont&#237;nuas e frequ&#234;ncias e porcentagens para vari&#225;veis categ&#243;ricas&#46; O teste Qui&#8208;Quadrado de Pearson e o teste exato de Fisher foram usados para compara&#231;&#227;o de grupos de vari&#225;veis categ&#243;ricas&#46; O teste U de Mann&#8208;Whitney foi utilizado para as compara&#231;&#245;es das vari&#225;veis cont&#237;nuas entre os grupos&#46; Acredita&#8208;se que somente um n&#237;vel baixo de IgE pode ser considerado tendo uma associa&#231;&#227;o com os resultados do tratamento com CsA<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">5</span></a> que confundiria as associa&#231;&#245;es apresentadas em artigos anteriores&#44; embora n&#227;o esteja totalmente confirmada&#46; Portanto&#44; foram utilizados modelos de regress&#227;o log&#237;stica multinomial para calcular ORs ajustados para n&#237;veis baixos &#40;&#60; 43&#41; de IgE &#40;aAORs&#41; para examinar as associa&#231;&#245;es entre os resultados do tratamento com CsA para UCE&#46; Os valores bilaterais de p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05 foram considerados estatisticamente significantes&#46;</p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Resultados</span><p id="par0135" class="elsevierStylePara elsevierViewall">Foram inclu&#237;dos 110 prontu&#225;rios de pacientes com UCE de sete centros &#40;74 mulheres &#91;67&#44;3&#37;&#93;&#44; com m&#233;dia de idade de 40&#44;98<span class="elsevierStyleHsp" style=""></span>&#177; 12&#44;37&#59; varia&#231;&#227;o&#58; 16&#8208;81 anos&#44; e dura&#231;&#227;o m&#233;dia da doen&#231;a de 57&#44;21<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>69&#44;31 meses&#59; varia&#231;&#227;o&#58; 6&#8208;402 meses&#41;&#46; As caracter&#237;sticas demogr&#225;ficas dos pacientes s&#227;o apresentadas na <a class="elsevierStyleCrossRef" href="#tbl0005">tabela 1</a>&#46; Quatro tipos de respostas ao tratamento foram assim distribu&#237;dos&#58; 47 &#40;42&#44;7&#37;&#41; Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; 15 &#40;13&#44;6&#37;&#41; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; 24 &#40;21&#44;8&#37;&#41; Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> e 24 &#40;21&#44;8&#37;&#41; Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46; Os achados laboratoriais dos pacientes s&#227;o apresentados na <a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a>&#46; Diferen&#231;as estatisticamente significantes&#44; bem como caracter&#237;sticas estatisticamente n&#227;o significantes&#44; por&#233;m mais frequentes&#44; s&#227;o apresentadas na <a class="elsevierStyleCrossRef" href="#tbl0015">tabela 3</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">N&#227;o h&#225; diferen&#231;as significantes entre Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span> e CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; mas algumas caracter&#237;sticas s&#227;o mais prevalentes no grupo CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span></span><p id="par0140" class="elsevierStylePara elsevierViewall">Quando foi feita a compara&#231;&#227;o entre os pacientes que responderam apenas ao Oma &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>47&#41; e apenas &#224; CsA &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&#41;&#44; n&#227;o houve diferen&#231;as estatisticamente significantes entre os grupos quanto aos par&#226;metros cl&#237;nicos e laboratoriais&#46; Mas o ASST positivo &#40;52&#44;8&#37; <span class="elsevierStyleItalic">vs</span>&#46; 71&#44;4&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;47&#41;&#44; hist&#243;ria familiar positiva &#40;4&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 20&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;086&#41;&#44; n&#237;veis elevados de PCR &#40;42&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 72&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;074&#41;&#44; basopenia &#40;2&#44;2&#37; <span class="elsevierStyleItalic">vs</span>&#46; 16&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;10&#41;&#44; eosinopenia &#40;0 <span class="elsevierStyleItalic">vs</span>&#46; 20&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;08&#41;&#44; altos n&#237;veis de VHS &#40;34&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 61&#44;5&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;07&#41;&#44; baixos n&#237;veis de IgE total &#40;20&#44;9&#37; <span class="elsevierStyleItalic">vs</span>&#46; 41&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;259&#41;&#44; positividade para anti&#8208;TPO &#40;37&#44;9&#37; <span class="elsevierStyleItalic">vs</span>&#46; 50&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;69&#41; e escores UCT basais mais baixos &#40;6 <span class="elsevierStyleItalic">vs</span>&#46; 3&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;122&#41; foram mais frequentes no grupo CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; mesmo que as diferen&#231;as n&#227;o tenham sido estatisticamente significantes&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Respondedores ao Oma t&#234;m escores UCT de linha basal mais altos em compara&#231;&#227;o com os n&#227;o respondedores ao Oma</span><p id="par0145" class="elsevierStylePara elsevierViewall">Quando o grupo Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span> &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>47&#41; foi comparado com o Oma&#8722;resp<span class="elsevierStyleSup">&#8722;</span> &#40;Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> e CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59; n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>39&#41;&#44; o &#250;nico par&#226;metro estatisticamente significante foi o escore UCT inicial&#44; o qual foi 6 <span class="elsevierStyleItalic">vs</span>&#46; 4&#44;5 em Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span><span class="elsevierStyleItalic">vs</span>&#46; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> e Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span>&#44; respectivamente &#40;p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;045&#41;&#46; Outras caracter&#237;sticas que foram observadas sem signific&#226;ncia estat&#237;stica no grupo Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span> foram maior taxa de pacientes do sexo masculino &#40;38&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 23&#44;1&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;13&#41;&#44; menor propor&#231;&#227;o de positividade no ASST &#40;52&#44;8&#37; <span class="elsevierStyleItalic">vs</span>&#46; 62&#44;5&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;45&#41;&#44; menor propor&#231;&#227;o de hist&#243;ria familiar &#40;4&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 15&#44;4&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;13&#41;&#44; menor frequ&#234;ncia de PCR alta &#40;42&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 55&#44;2&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;29&#41;&#44; menor frequ&#234;ncia de eosinopenia &#40;0&#37; <span class="elsevierStyleItalic">vs</span>&#46; 13&#44;6&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;10&#41;&#44; menor frequ&#234;ncia de basopenia &#40;2&#44;2&#37; <span class="elsevierStyleItalic">vs</span>&#46; 9&#44;4&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;30&#41;&#44; menor frequ&#234;ncia de altos n&#237;veis de VHS &#40;34&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 44&#44;1&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;36&#41;&#44; menor frequ&#234;ncia de angioedema &#40;57&#44;4&#37; <span class="elsevierStyleItalic">vs</span>&#46; 69&#44;2&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;26&#41;&#44; menor frequ&#234;ncia de doen&#231;a autoimune da tireoide &#40;22&#44;9&#37; <span class="elsevierStyleItalic">vs</span>&#46; 26&#44;9&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;71&#41; e maior frequ&#234;ncia de IgE total<span class="elsevierStyleHsp" style=""></span>&#62; 43 &#40;79&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 66&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;22&#41;&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">N&#237;veis elevados de PCR s&#227;o mais frequentes em respondedores &#224; CsA em compara&#231;&#227;o com n&#227;o respondedores &#224; CsA</span><p id="par0150" class="elsevierStylePara elsevierViewall">A &#250;nica diferen&#231;a estatisticamente significante entre CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&#41; e CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> &#40;Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span>&#44; Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span> e Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59; n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>95&#41; foram altos n&#237;veis de PCR&#44; o que foi mais frequente em CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> &#40;72&#44;7&#37; <span class="elsevierStyleItalic">vs</span>&#46; 40&#44;3&#37;&#59; OR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>3&#44;96&#44; IC 95&#37; 0&#44;97&#8208;16&#44;1&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;05&#41; e ter altos n&#237;veis de PCR aumentou a chance de resposta favor&#225;vel ao tratamento com CsA em 6&#44;1 ap&#243;s ajuste para n&#237;veis baixos de IgE total &#40;ORa<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>6&#44;1&#59; IC 95&#37; 1&#44;17&#8208;31&#44;8&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;032&#41;&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">Hist&#243;ria familiar positiva &#40;20&#37; <span class="elsevierStyleItalic">vs</span>&#46; 8&#44;4&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;172&#41;&#44; ASST positivo &#40;71&#44;4&#37; <span class="elsevierStyleItalic">vs</span>&#46; 55&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;692&#41;&#44; eosinopenia &#40;20&#37; <span class="elsevierStyleItalic">vs</span>&#46; 2&#44;3&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;085&#41;&#44; basopenia &#40;16&#44;7&#37; <span class="elsevierStyleItalic">vs</span>&#46; 2&#44;2&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;067&#41;&#44; altos n&#237;veis de VHS &#40;61&#44;5&#37; <span class="elsevierStyleItalic">vs</span>&#46; 36&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;08&#41;&#44; n&#237;veis mais baixos de IgE total &#40;41&#44;7&#37; <span class="elsevierStyleItalic">vs</span>&#46; 22&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;159&#41;&#44; positividade anti&#8208;TPO &#40;50&#37; <span class="elsevierStyleItalic">vs</span>&#46; 32&#44;8&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;436&#41;&#44; escores UCT basais mais baixos &#40;3 <span class="elsevierStyleItalic">vs</span>&#46; 7&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;107&#41; foram mais frequentes&#44; embora sem signific&#226;ncia estat&#237;stica&#44; no grupo CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Sexo feminino e escore UCT de linha basal mais baixo foram mais frequentes em n&#227;o respondedores a qualquer um dos dois medicamentos</span><p id="par0160" class="elsevierStylePara elsevierViewall">Os n&#227;o respondedores a qualquer um dos dois medicamentos foram comparados com os grupos respondedores &#40;Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> e Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#41; e a compara&#231;&#227;o revelou que a maioria dos Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> era do sexo feminino &#40;21&#59; 87&#44;5&#37; <span class="elsevierStyleItalic">vs</span>&#46; 53&#59; 61&#44;6&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;017&#41; e o escore UCT basal foi menor em Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> &#40;5 <span class="elsevierStyleItalic">vs</span>&#46; 7&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;06&#41;&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Respondedores a ambos os medicamentos tiveram menos angioedema e escore UCT basal mais alto</span><p id="par0165" class="elsevierStylePara elsevierViewall">O grupo Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> foi comparado com o restante dos pacientes &#40;Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> e Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span>&#41;&#46; A frequ&#234;ncia de angioedema foi menor &#40;8&#59; 33&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 54&#59; 62&#44;8&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;01&#41; e o escore UCT de linha basal foi maior no grupo Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> &#40;8 <span class="elsevierStyleItalic">vs</span>&#46; 5&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;017&#41;&#46;</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Discuss&#227;o</span><p id="par0170" class="elsevierStylePara elsevierViewall">O presente estudo mostrou que&#44; em uma subpopula&#231;&#227;o de pacientes com UCE refrat&#225;ria aos anti&#8208;histam&#237;nicos que receberam Oma e CsA em algum momento durante o seguimento&#44; a maioria &#40;40&#37;&#41; respondeu ao Oma&#44; a minoria &#40;10&#37;&#41; respondeu &#224; CsA&#44; enquanto 20&#37; responderam a ambos&#44; e outros 20&#37; n&#227;o responderam a nenhum dos dois medicamentos &#40;resumo dos achados na <a class="elsevierStyleCrossRef" href="#tbl0020">tabela 4</a>&#41;&#46; Esses achados s&#227;o interessantes em virtude dos relatos de altas taxas de resposta de pacientes com UCE ao tratamento com CsA&#44; que variaram de 38 a 100&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">6</span></a> Seria esperado que mais pacientes respondessem ao tratamento com CsA&#59; entretanto&#44; ap&#243;s um exame cuidadoso dos achados cl&#237;nicos e laboratoriais da popula&#231;&#227;o de pacientes do presente estudo&#44; verificou&#8208;se que 65&#37; da popula&#231;&#227;o de pacientes tinha n&#237;veis elevados de IgE total &#40;&#62; 100 UI&#47;mL&#41;&#44;o que foi relatado como uma caracter&#237;stica da UCE autoimune tipo I e um fator desfavor&#225;vel para a resposta ao tratamento com CsA&#46;<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">3&#44;5</span></a> Maurer et al&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">3</span></a> descreveram algumas caracter&#237;sticas da UCE autoimune tipo I <span class="elsevierStyleItalic">versus</span> tipo IIb e apontaram que a presen&#231;a de auto&#8208;IgE &#40;p&#46; ex&#46;&#44; contra TPO&#44; IL&#8208;24&#44; ds&#8208;DNA&#41;&#44; taxas mais altas de doen&#231;as al&#233;rgicas concomitantes&#44; n&#237;veis de IgE total normais ou elevados e alta taxa de resposta ao Oma favorecem a UCE autoimune tipo I&#44; enquanto a presen&#231;a de auto&#8208;IgG &#40;contra IgE&#44; Fc&#603;RI&#41;&#44; maior atividade da doen&#231;a&#44; maior dura&#231;&#227;o da doen&#231;a&#44; maiores taxas de doen&#231;as autoimunes concomitantes&#44; menores n&#237;veis de IgE total&#44; maiores taxas de eosinopenia e basopenia&#44; n&#237;veis mais elevados de PCR&#44; maiores taxas de positividade para ANA&#44; indicam baixa taxa de resposta ou resposta mais lenta ao Oma e boa resposta ao tratamento imunossupressor&#46; Com base nessa classifica&#231;&#227;o de end&#243;tipo&#44; &#233; poss&#237;vel explicar por que a taxa de resposta &#224; CsA &#233; baixa nessa popula&#231;&#227;o de pacientes&#59; acredita&#8208;se na baixa frequ&#234;ncia de pacientes com eosinopenia&#44; basopenia&#44; baixos n&#237;veis de IgE&#44; altos n&#237;veis de PCR e alta gravidade da doen&#231;a&#59; mas a alta frequ&#234;ncia de pacientes com altos n&#237;veis de IgE total mostra que a maioria dessa popula&#231;&#227;o de pacientes &#233; composta por UCE autoimune tipo I e&#44; portanto&#44; mais propensa a responder ao tratamento com Oma&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0175" class="elsevierStylePara elsevierViewall">A busca por biomarcadores que possam predizer a resposta a um determinado tratamento tem sido um assunto de interesse e muitas publica&#231;&#245;es relataram que alguns biomarcadores podem ser &#250;teis na determina&#231;&#227;o da resposta a certos tratamentos na UCE&#46; Para o Oma&#44; altos n&#237;veis de IgE&#44; negatividade no ASST&#44; negatividade de BHRA&#44; a falta de atividade de up&#8208;regula&#231;&#227;o de bas&#243;filos CD203c&#44; alta express&#227;o de bas&#243;filos Fc&#603;RI e n&#237;veis mais baixos de IL&#8208;31 foram relatados como biomarcadores para boa resposta ao tratamento&#44; enquanto para ciclosporina&#44; positividade de BHRA&#44; n&#237;veis mais altos de PCR&#44; n&#237;veis baixos de IgE&#44; positividade no ASST&#44; n&#237;veis baixos de d&#237;mero&#8208;<span class="elsevierStyleSmallCaps">D</span>&#44; alta atividade da doen&#231;a e curta dura&#231;&#227;o da doen&#231;a foram indicativos de boa resposta ao tratamento&#46;<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">4&#44;7</span></a> Na popula&#231;&#227;o do presente estudo&#44; n&#227;o houve diferen&#231;a estatisticamente significante entre os respondedores ao Oma e CsA em rela&#231;&#227;o aos par&#226;metros de compara&#231;&#227;o&#44; mas isso pode ter sido em virtude da distribui&#231;&#227;o desequilibrada de pacientes com determinados par&#226;metros&#46; Como mencionado anteriormente&#44; havia um percentual menor de pacientes com boa resposta ao tratamento com CsA&#44; o que pode ter resultado em limita&#231;&#227;o da an&#225;lise estat&#237;stica&#59; isso se deve principalmente &#224; escolha do Oma como tratamento de primeira linha em pacientes refrat&#225;rios aos anti&#8208;histam&#237;nicos&#46; A compara&#231;&#227;o entre os grupos mostrou que ASST positivo&#44; hist&#243;ria familiar positiva&#44; altos n&#237;veis de PCR&#44; basopenia&#44; eosinopenia&#44; altos n&#237;veis de VHS&#44; baixos n&#237;veis de IgE total&#44; positividade anti&#8208;TPO e escores UCT basais mais baixos foram mais frequentes em respondedores &#224; CsA do que respondedores ao Oma&#46; Esses achados referem&#8208;se novamente &#224; import&#226;ncia dos end&#243;tipos de UCE&#59; os par&#226;metros mencionados associados &#224; resposta &#224; CsA tamb&#233;m s&#227;o caracter&#237;sticas da UCE autoimune do tipo IIb&#46; A urtic&#225;ria autoimune tipo IIb &#233; definida por autoanticorpos IgG anti&#8208;IgE ou Fc&#603;RI&#44; teste de ativa&#231;&#227;o de bas&#243;filos &#40;BAT&#44; <span class="elsevierStyleItalic">basophil activation test</span>&#41; positivo e um ASST positivo e demonstrou responder melhor ao tratamento com CsA&#46;<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">8&#8211;11</span></a> Tamb&#233;m foi demonstrado que pacientes com n&#237;veis elevados de PCR responderam melhor &#224; CsA&#44; o que &#233; um achado relatado em estudos anteriores&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">12</span></a> Al&#233;m disso&#44; foi observado que n&#237;veis baixos de IgE total foram mais frequentes em respondedores &#224; CsA&#44; como relatado por Santiago et al&#46;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">5</span></a> Semelhante aos achados de Hollander et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">11</span></a> que relataram que a gravidade inicial mais alta predizia uma resposta bem&#8208;sucedida ao tratamento com CsA&#44; os respondedores &#224; CsA no presente estudo tinham escores UCT mais baixos&#46; Embora os respondedores &#224; CsA no presente estudo tivessem apresentado maior frequ&#234;ncia de positividade de ASST&#44; a evid&#234;ncia de ASST ser um potencial preditor de resposta ao tratamento com CsA n&#227;o foi conclusiva&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">Observou&#8208;se que os respondedores ao Oma nessa popula&#231;&#227;o estudada apresentavam escore UCT basal significantemente mais alto do que os n&#227;o respondedores ao Oma&#44; o que indicou atividade de doen&#231;a menor&#46; Esse fato tamb&#233;m foi relatado por Salman et al&#46;<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">13</span></a> A presen&#231;a de angioedema&#44;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">14</span></a> sexo feminino&#44;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">15</span></a> n&#237;veis elevados de PCR&#44;<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">16</span></a> positividade de ASST&#44;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">17</span></a> eosinopenia e basopenia<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">18</span></a> estiveram associadas &#224; resposta insatisfat&#243;ria ao Oma&#46; N&#237;veis s&#233;ricos mais altos de IgE total s&#227;o atualmente aceitos como biomarcador estabelecido da resposta ao Oma&#44;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">14</span></a> embora n&#227;o tenha sido estatisticamente significante no presente estudo&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">Um em cada cinco pacientes do presente estudo apresentou resposta a ambos os medicamentos&#44; e esses pacientes apresentaram menos angioedema e escores UCT basais mais altos &#40;menor atividade basal da doen&#231;a&#41;&#44; que s&#227;o caracter&#237;sticas de menor atividade da doen&#231;a&#46; Uma resposta favor&#225;vel ao tratamento &#233; prevista em pacientes com menor atividade da doen&#231;a&#59; entretanto&#44; seria esclarecedor se fosse poss&#237;vel realizar testes para autoanticorpos IgE e IgG e determinar que tipo de autoimunidade esses pacientes t&#234;m&#46; Dessa maneira&#44; a hip&#243;tese de que esses pacientes podem ter ambos os tipos de autoanticorpos e&#44; portanto&#44; ambos os tipos de autoimunidade poderia ser considerada&#46; A ideia da presen&#231;a de tais pacientes vem das observa&#231;&#245;es de relatos crescentes de pacientes que respondem ao tratamento conjunto com Oma e CsA&#46; Mas os pacientes nesses relatos n&#227;o parecem responder ao tratamento com Oma ou CsA isoladamente&#44; mas ao tratamento com um regime combinado&#44; refletindo pacientes com alta atividade da doen&#231;a e possivelmente com dois tipos de autoimunidade&#46;<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">19&#8211;21</span></a> A exist&#234;ncia conjunta de dois tipos de autoimunidade foi demonstrada em um estudo cl&#237;nico recente de Asero et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">22</span></a> que mostraram a coexist&#234;ncia de autoanticorpos IgE e IgG para receptores IgE de alta e baixa afinidade &#40;Fc&#603;RI e Fc&#603;RII&#41;&#44; fator tecidual e tireoglobulina&#44; principalmente em respondedores tardios ao Oma&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">Vinte por cento dos pacientes neste estudo n&#227;o responderam ao tratamento com Oma ou CsA&#46; Essa popula&#231;&#227;o de pacientes refrat&#225;rios incluiu mais mulheres e mais pacientes com escores UCT de linha basal mais baixos&#46; Essas caracter&#237;sticas tamb&#233;m foram associadas &#224; doen&#231;a refrat&#225;ria em relatos anteriores&#59; o sexo feminino foi relatado como sendo um preditor de maior tempo at&#233; a remiss&#227;o&#44;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">23</span></a> resist&#234;ncia aos anti&#8208;histam&#237;nicos<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">24</span></a> e maior frequ&#234;ncia de recorr&#234;ncia ap&#243;s o tratamento com Oma&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">25</span></a> Escores de UCT basais mais baixos foram associados &#224; taxa de resposta mais baixa e maior necessidade de aumento da dose de Oma&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">26</span></a> Apesar de n&#227;o ter signific&#226;ncia estat&#237;stica&#44; os pacientes refrat&#225;rios apresentaram maior taxa de positividade para <span class="elsevierStyleItalic">H&#46; pylori</span>&#44; embora n&#227;o haja informa&#231;&#245;es sobre as taxas de erradica&#231;&#227;o do <span class="elsevierStyleItalic">H&#46; pylori</span> nesses pacientes&#46; Isso enfatiza a import&#226;ncia de avaliar e tratar comorbidades em pacientes com UCE&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">O &#250;nico estudo que se assemelha em alguns aspectos ao presente trabalho &#233; o publicado por S&#225;nchez et al&#46;&#44; em que relataram que&#44; de 88 pacientes em seu estudo&#44; 26&#47;88 &#40;29&#44;5&#37;&#41; responderam &#224; CsA&#44; 41&#47;88 &#40;46&#44;5&#37;&#41; responderam ao Oma&#44; 16&#47;88 &#40;18&#44;2&#37;&#41; responderam quando CsA e Oma foram combinados e apenas cinco &#40;5&#44;6&#37;&#41; pacientes permaneceram sem resposta ao tratamento&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">19</span></a> As taxas de resposta ao Oma foram semelhantes &#224;s do presente estudo e tamb&#233;m foram semelhantes &#224; taxa de resposta completa relatada pelos ensaios cl&#237;nicos e estudos da pr&#225;tica cl&#237;nica do Oma&#44; que &#233; de aproximadamente 40 a 50&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">27</span></a> Contudo&#44; a taxa de n&#227;o respondedores a ambos os medicamentos parece ser muito menor do que no presente estudo&#44; o que pode ser atribu&#237;do &#224; prefer&#234;ncia do &#250;ltimo de n&#227;o incluir pacientes que utilizaram Oma e CsA ao mesmo tempo&#46; Se esses pacientes refrat&#225;rios fossem tratados com ambos os medicamentos&#44; a taxa de n&#227;o respondedores poderia ter sido menor&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">A raz&#227;o pela qual esses pacientes n&#227;o respondem nem ao Oma nem &#224; CsA precisa ser explorada em estudos prospectivos maiores&#44; que avaliem o perfil dos pacientes com exames laboratoriais detalhados&#44; incluindo autoanticorpos tipo IgG e IgE&#44; testes BAT&#47;BHRA&#44; bem como outros mediadores inflamat&#243;rios&#44; tanto na pele quanto no sangue perif&#233;rico&#46; Esses pacientes podem ter um mecanismo patol&#243;gico subjacente diferente&#44; incluindo envolvimento de componentes do complemento&#44; infiltrados na pele compostos por eosin&#243;filos ou linf&#243;citos T produzindo outras citoquinas inflamat&#243;rias&#44; como IL&#8208;4&#44; IL&#8208;5&#44; IL&#8208;23&#44; IL&#8208;17 ou IL&#8208;31&#44; ou outros mecanismos&#44; incluindo angiog&#234;nese&#44; coagula&#231;&#227;o e desregula&#231;&#227;o vascular&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">28</span></a> H&#225; muitas varia&#231;&#245;es diferentes de op&#231;&#245;es terap&#234;uticas para esse grupo de pacientes refrat&#225;rios que est&#227;o sendo utilizados em ensaios cl&#237;nicos em progresso ou sob desenvolvimento&#44; incluindo dupilumabe&#44; fenebrutinibe&#44; benralizumabe e anti&#8208;siglec&#8208;8&#46;<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">2&#44;29</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">As limita&#231;&#245;es do presente estudo compreendem a sua natureza retrospectiva&#44; que n&#227;o incluiu o mesmo n&#250;mero de pacientes nos quatro grupos delineados&#44; n&#227;o incluindo pacientes que foram tratados tanto com CsA quanto com Oma&#44; um baixo n&#250;mero de pacientes&#44; a falta de um grupo controle e a falta de testes BAT ou BHRA&#46; A natureza transversal do estudo levou a uma popula&#231;&#227;o de estudo que pode n&#227;o refletir a popula&#231;&#227;o geral com UCE&#44; mas a natureza multic&#234;ntrica do estudo pode ter atenuado esse efeito&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conclus&#227;o</span><p id="par0210" class="elsevierStylePara elsevierViewall">A categoriza&#231;&#227;o de pacientes em end&#243;tipos pode ser &#250;til para prever as respostas ao tratamento e pode ajudar na escolha da op&#231;&#227;o mais adequada de tratamento para cada paciente com UCE&#46; Para o melhor cuidado dos pacientes&#44; determinar a atividade da doen&#231;a na linha basal e orientar a avalia&#231;&#227;o e o manejo de comorbidades s&#227;o de grande import&#226;ncia&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Suporte financeiro</span><p id="par0215" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Contribui&#231;&#227;o dos autores</span><p id="par0220" class="elsevierStylePara elsevierViewall">Emek Kocaturk&#58; Contribui&#231;&#245;es substanciais para a concep&#231;&#227;o e planejamento do estudo&#59; Obten&#231;&#227;o&#44; an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica da literatura&#59; Participa&#231;&#227;o na reda&#231;&#227;o do manuscrito&#59; escrita do manuscrito&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">Emel B&#252;lb&#252;l Ba&#351;kan&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0230" class="elsevierStylePara elsevierViewall">&#214;zlem Su K&#252;&#231;&#252;k&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">Mustafa &#214;zdemir&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Sinem &#214;rnek&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Participa&#231;&#227;o efetiva na orienta&#231;&#227;o da pesquisa&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall">Pelin Kuteyla Can&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Participa&#231;&#227;o efetiva na orienta&#231;&#227;o da pesquisa&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0250" class="elsevierStylePara elsevierViewall">Eda Ha&#351;al&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Participa&#231;&#227;o efetiva na orienta&#231;&#227;o da pesquisa&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0255" class="elsevierStylePara elsevierViewall">Burhan Engin&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0260" class="elsevierStylePara elsevierViewall">Nilg&#252;n Atakan&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0265" class="elsevierStylePara elsevierViewall">Erkan Alpsoy&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Conflito de interesses</span><p id="par0270" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres1767850"
          "titulo" => "Resumo"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Fundamentos"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Objetivo"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "M&#233;todos"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Resultados"
            ]
            4 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Limita&#231;&#245;es do estudo"
            ]
            5 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Conclus&#245;es"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1554162"
          "titulo" => "Palavras&#8208;chave"
        ]
        2 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introdu&#231;&#227;o"
        ]
        3 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "M&#233;todos"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Defini&#231;&#245;es"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "An&#225;lise estat&#237;stica"
            ]
          ]
        ]
        4 => array:3 [
          "identificador" => "sec0025"
          "titulo" => "Resultados"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "N&#227;o h&#225; diferen&#231;as significantes entre Oma&#8722;resp e CsA&#8722;resp&#44; mas algumas caracter&#237;sticas s&#227;o mais prevalentes no grupo CsA&#8722;resp"
            ]
            1 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Respondedores ao Oma t&#234;m escores UCT de linha basal mais altos em compara&#231;&#227;o com os n&#227;o respondedores ao Oma"
            ]
            2 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "N&#237;veis elevados de PCR s&#227;o mais frequentes em respondedores &#224; CsA em compara&#231;&#227;o com n&#227;o respondedores &#224; CsA"
            ]
            3 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Sexo feminino e escore UCT de linha basal mais baixo foram mais frequentes em n&#227;o respondedores a qualquer um dos dois medicamentos"
            ]
            4 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Respondedores a ambos os medicamentos tiveram menos angioedema e escore UCT basal mais alto"
            ]
          ]
        ]
        5 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Discuss&#227;o"
        ]
        6 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Conclus&#227;o"
        ]
        7 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Suporte financeiro"
        ]
        8 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Contribui&#231;&#227;o dos autores"
        ]
        9 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conflito de interesses"
        ]
        10 => array:1 [
          "titulo" => "Refer&#234;ncias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-01-05"
    "fechaAceptado" => "2022-03-07"
    "PalabrasClave" => array:1 [
      "pt" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palavras&#8208;chave"
          "identificador" => "xpalclavsec1554162"
          "palabras" => array:4 [
            0 => "Biomarcadores"
            1 => "Ciclosporina"
            2 => "Omalizumabe"
            3 => "Urtic&#225;ria cr&#244;nica"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "pt" => array:3 [
        "titulo" => "Resumo"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Fundamentos</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A urtic&#225;ria cr&#244;nica espont&#226;nea &#40;UCE&#41; &#233; caracterizada por urticas e&#47;ou angioedema recorrentes por mais de seis semanas&#46; As diretrizes recomendam omalizumabe &#40;Oma&#41; como tratamento de primeira linha e ciclosporina&#8208;A &#40;CsA&#41; como tratamento de segunda linha em UCE resistentes aos anti&#8208;histam&#237;nicos&#46; Esse algoritmo gradativo pode ser demorado e caro&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objetivo</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Determinar indicadores de resposta ao Oma ou &#224; CsA em pacientes com UCE&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">M&#233;todos</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Foram analisados retrospectivamente dados de sete centros da Turquia&#59; os crit&#233;rios de inclus&#227;o para os pacientes foram receber tratamento com Oma e CsA &#40;n&#227;o simultaneamente&#41; em algum momento durante o seguimento&#46; As caracter&#237;sticas cl&#237;nicas e laboratoriais foram analisadas e comparadas entre os grupos&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Resultados</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">De 110 pacientes com UCE&#44; 47 &#40;42&#44;7&#37;&#41; responderam ao Oma&#44; 15 &#40;13&#44;6&#37;&#41; responderam &#224; CsA&#44; 24 &#40;21&#44;8&#37;&#41; responderam ao Oma e &#224; CsA e 24 &#40;21&#44;8&#37;&#41; n&#227;o responderam a nenhum dos dois medicamentos&#46; N&#237;veis elevados de PCR foram mais frequentes em respondedores &#224; CsA &#40;72&#44;7&#37; <span class="elsevierStyleItalic">vs</span>&#46; 40&#44;3&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;055&#41;&#46; Os respondedores ao Oma tiveram escores ao teste de controle da urtic&#225;ria &#40;UCT&#41; basais mais altos &#40;6 <span class="elsevierStyleItalic">vs</span>&#46; 4&#44;5&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;045&#41;&#46; Os respondedores a ambos os medicamentos tiveram menos angioedema e escores UCT basais mais altos em compara&#231;&#227;o com outros grupos &#40;33&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 62&#44;8&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;01 e 8 <span class="elsevierStyleItalic">vs</span>&#46; 5&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;017&#41;&#46; Os n&#227;o&#8208;respondedores a ambos os medicamentos apresentaram maior frequ&#234;ncia no sexo feminino e escores UCT basais mais baixos em compara&#231;&#227;o aos outros grupos &#40;87&#44;5&#37; <span class="elsevierStyleItalic">vs</span>&#46; 61&#44;6&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;017 e 5 <span class="elsevierStyleItalic">vs</span>&#46; 7&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;06&#41;&#46;</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Limita&#231;&#245;es do estudo</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Natureza retrospectiva&#44; n&#227;o haver n&#250;meros iguais de pacientes em cada grupo&#44; n&#250;mero limitado de pacientes&#44; nenhum grupo controle&#44; falta de teste de ativa&#231;&#227;o de bas&#243;filos &#40;BAT&#41; ou teste de BHRA &#40;ensaio de libera&#231;&#227;o de histamina de bas&#243;filos&#41;&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Conclus&#245;es</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">A avalia&#231;&#227;o basal da atividade da doen&#231;a&#44; que considera a presen&#231;a de angioedema e escores de atividade da doen&#231;a&#44; sexo e n&#237;veis de PCR&#44; pode ser &#250;til para prever os resultados do tratamento em pacientes com UCE e escolher o tratamento mais adequado para cada paciente&#46; A categoriza&#231;&#227;o de pacientes em end&#243;tipos espec&#237;ficos pode otimizar e aumentar o sucesso do tratamento&#46;</p></span>"
        "secciones" => array:6 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Fundamentos"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Objetivo"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "M&#233;todos"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Resultados"
          ]
          4 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Limita&#231;&#245;es do estudo"
          ]
          5 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Conclus&#245;es"
          ]
        ]
      ]
    ]
    "NotaPie" => array:2 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Como citar este artigo&#58; Kocat&#252;rk E&#44; Ba&#351;kan EB&#44; K&#252;&#231;&#252;k OS&#44; &#214;zdemir M&#44; &#214;rnek S&#44; Can PK&#44; et al&#46; Omalizumab versus cyclosporin&#8208;A for the treatment of chronic spontaneous urticaria&#58; can we define better&#8208;responding endotypes&#63; An Bras Dermatol&#46; 2022&#59;97&#58;592&#8211;600&#46;</p>"
      ]
      1 => array:2 [
        "etiqueta" => "&#9734;&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Trabalho realizado no Departamento de Dermatologia&#44; Koc University&#44; Escola de Medicina&#44; Istambul&#44; Turquia&#59; Departamento de Dermatologia&#44; Uludag University&#44; Escola de Medicina&#44; Bursa&#44; Turquia&#59; Departamento de Dermatologia&#44; Bezmialem Vakif University&#44; Escola de Medicina&#44; Istambul&#44; Turquia&#59; Departamento de Dermatologia&#44; Istanbul Medipol University&#44; Escola de Medicina&#44; Istambul&#44; Turquia&#59; Departamento de Dermatologia&#44; Ankara Diskapi Yildirim Beyazit Training and Research Hospital&#44; Ankara&#44; Turquia&#59; Departamento de Dermatologia&#44; VM Medical Park Maltepe Hospital&#44; Istanbul&#44; Turquia&#59; Departamento de Dermatologia&#44; Istanbul University&#44; Escola de Medicina Cerrahpasa&#44; Istanbul&#44; Turquia&#59; Departamento de Dermatologia&#44; Hacettepe University&#44; Escola de Medicina&#44; Ankara&#44; Turquia&#59; Departamento de Dermatologia&#44; Akdeniz University&#44; Escola de Medicina&#44; Antalya&#44; Turquia&#46;</p>"
      ]
    ]
    "multimedia" => array:5 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1672
            "Ancho" => 1675
            "Tamanyo" => 197262
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Distribui&#231;&#227;o dos quatro tipos de respostas ao tratamento da UCE&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabela 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">UCI&#44; urtic&#225;ria cr&#244;nica induzida&#59; UCT&#44; teste de controle da urtic&#225;ria&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Par&#226;metros cl&#237;nicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>110&#44; &#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor ao omalizumabe &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>47&#44; 42&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor &#224; ciclosporina &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&#44; 13&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor a ambos&#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&#44;21&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#227;o respondedor &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&#44; 21&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Idade em anos</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#237;n&#8208;M&#225;x &#40;Mediana&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&#8208;81 &#40;39&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#8208;81 &#40;42&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&#8208;73 &#40;37&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21&#8208;66 &#40;34&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&#8208;69 &#40;37&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#233;dia<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#44;98<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#44;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">43&#44;32<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>10&#44;67&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#44;20<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>16&#44;52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&#44;79<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#44;18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#44;08<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#44;64&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Sexo n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Masculino&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36 &#40;32&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;38&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;40&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;37&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Feminino&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">74 &#40;67&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29 &#40;61&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;60&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;62&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;87&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Acompanhado de UCI n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;21&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;20&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;17&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dura&#231;&#227;o da doen&#231;a &#40;meses&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#237;n&#8208;M&#225;x &#40;Mediana&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8208;402 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8208;300 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#8208;120 &#40;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8208;264 &#40;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#8208;402 &#40;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#233;dia<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57&#44;21<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>69&#44;31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">60&#44;32<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>71&#44;26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45&#44;53<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>38&#44;33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&#44;46<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>63&#44;72&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">64&#44;17<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>86&#44;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Angioedema&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">62 &#40;56&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;57&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;66&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;70&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UCT basal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#237;n&#8208;M&#225;x &#40;Mediana&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8208;16 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#8208;16 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8208;9 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#8208;16 &#40;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8208;11 &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#233;dia<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>4&#44;34&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#44;44<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>4&#44;65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#44;75<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;06&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#44;12<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#44;11<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;53&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UCT &#8805; 6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46 &#40;55&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;56&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;37&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;81&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;38&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UCT &#60;<span class="elsevierStyleHsp" style=""></span>6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;44&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;43&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;62&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;18&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;61&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hist&#243;ria familiar positiva&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;10&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;4&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas demogr&#225;ficas e cl&#237;nico-laboratoriais dos pacientes</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabela 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">anti&#8208;TG&#44; anticorpo antitireoglobulina&#59; anti&#8208;TPO&#44; anticorpos antiperoxidase&#59; PCR&#44; prote&#237;na C reativa&#59; VHS&#44; velocidade de hemossedimenta&#231;&#227;o&#59; <span class="elsevierStyleItalic">H&#46; pylori</span>&#44; <span class="elsevierStyleItalic">Helicobacter pylori</span>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Achado laboratorial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>1100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor ao omalizumabe&#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>47&#44; 42&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor &#224; ciclosporina &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&#44; 13&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor a ambos &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&#44; 21&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#227;o respondedor &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&#44; 21&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altos n&#237;veis de PCR</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>88&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">39 &#40;44&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16 &#40;42&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;72&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;44&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altos n&#237;veis de VHS</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">39 &#40;39&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;34&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;61&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;42&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Eosinopenia</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>23&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;5&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;8&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Basopenia</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>102&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;3&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;2&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;16&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positividade no ASST</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>77&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44 &#40;57&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19 &#40;52&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;71&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;58&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;58&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#237;veis s&#233;ricos totais de IgE &#40;IU&#47;mL&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;03&#8208;6350 &#40;167&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#44;28&#8208;6350 &#40;169&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;03&#8208;1282 &#40;280&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#44;43&#8208;1606 &#40;150&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#8208;1434 &#40;172&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">370&#44;65<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>727&#44;22&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">476&#44;35<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1000&#44;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">343&#44;27<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>392&#44;27&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">252&#44;58<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>368&#44;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">271&#44;05<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>328&#44;70&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#237;veis s&#233;ricos totais de IgE &#60;<span class="elsevierStyleHsp" style=""></span>43 &#40;IU&#47;mL&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>94&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;24&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;20&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;41&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;16&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;28&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doen&#231;a autoimune da tireoide</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>35&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;21&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;22&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;22&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;10&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;29&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altos n&#237;veis de anticorpo anti&#8208;TPO&#44; n &#40;&#37;&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>72&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>29&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;34&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;37&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;50&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;21&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;37&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altos n&#237;veis de anticorpo anti&#8208;TG&#44; n &#40;&#37;&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>66&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;27&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;32&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;15&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;35&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ant&#237;geno para <span class="elsevierStyleItalic">H&#46; pylori</span> positivo nas fezes&#44; n &#40;&#37;&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>87&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;35&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;31&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;36&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;46&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Achados laboratoriais dos pacientes em cada grupo</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabela 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">anti&#8208;TPO&#44; anticorpo antitireoide peroxidase&#59; anti&#8208;TG&#44; anticorpo antitireoglobulina&#59; ASST&#44; teste cut&#226;neo com soro aut&#243;logo&#59; PCR&#44; prote&#237;na C reativa&#59; CsA&#44; ciclosporina&#8208;A&#59; VHS&#44; velocidade de hemossedimenta&#231;&#227;o&#59; <span class="elsevierStyleItalic">H&#46; pilori</span>&#44; <span class="elsevierStyleItalic">Helicobacter pylori</span>&#59; Oma&#44; omalizumabe&#59; UCT&#44; teste de controle de urtic&#225;ria&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Grupo tratamento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">p<span class="elsevierStyleHsp" style=""></span>&#62; 0&#44;05&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores ao Oma &#40;somente&#41; <span class="elsevierStyleItalic">vs</span>&#46; respondedores &#224; CsA &#40;somente&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nenhum&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; ASST positivo&#44; hist&#243;ria familiar positiva&#44; PCR alta&#44; basopenia&#44; eosinopenia&#44; VHS alta&#44; n&#237;veis baixos de IgE total&#44; positividade para anti&#8208;TPO&#44; escores UCT basais mais baixos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores ao Oma <span class="elsevierStyleItalic">vs</span>&#46; n&#227;o respondedores ao Oma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais alto em respondedores ao Oma&#58; escore UCT basal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequentes em respondedores ao Oma&#58; sexo masculino&#44; menores taxas de positividade para ASST&#44; menores taxas de hist&#243;ria familiar&#44; menor frequ&#234;ncia de PCR alta&#44; menor frequ&#234;ncia de eosinopenia&#44; menor frequ&#234;ncia de basopenia&#44; menor frequ&#234;ncia de altos n&#237;veis de VHS&#44; menor frequ&#234;ncia de angioedema&#44; menor frequ&#234;ncia de doen&#231;a autoimune da tireoide&#44; maior frequ&#234;ncia de n&#237;veis totais de IgE<span class="elsevierStyleHsp" style=""></span>&#62; 43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores &#224; CsA <span class="elsevierStyleItalic">vs</span>&#46; n&#227;o respondedores &#224; CsA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; Altos n&#237;veis de PCR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; hist&#243;ria familiar positiva&#44; ASST positivo&#44; eosinopenia&#44; basopenia&#44; altos n&#237;veis de VHS&#44; n&#237;veis mais baixos de IgE total&#44; positividade anti&#8208;TPO&#44; escores UCT basais mais baixos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores a ambos os medicamentos <span class="elsevierStyleItalic">vs</span>&#46; outros tr&#234;s grupos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores a ambos os medicamentos&#58; menor frequ&#234;ncia de angioedema&#44; maior UCT basal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Menos frequente em respondedores a ambos os medicamentos&#58; PCR alta&#44; eosinopenia&#44; basopenia&#44; doen&#231;a autoimune da tireoide&#44; positividade para anti&#8208;TPO&#44; positividade para anti&#8208;TG&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#227;o respondedores a ambos os medicamentos <span class="elsevierStyleItalic">vs</span>&#46; outros tr&#234;s grupos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Maior frequ&#234;ncia em n&#227;o respondedores&#58; sexo feminino&#44; UCT basal inferior&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Maior frequ&#234;ncia em n&#227;o respondedores&#58; Angioedema&#44; doen&#231;a autoimune da tireoide&#44; positividade anti&#8208;TG&#44; <span class="elsevierStyleItalic">H&#46; pylori</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores &#224; CsA versus n&#227;o respondedores a CsA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; PCR alta&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; hist&#243;ria familiar positiva&#44; ASST positivo&#44; eosinopenia&#44; basopenia&#44; altos n&#237;veis de VHS&#44; n&#237;veis mais baixos de IgE total&#44; positividade para anti&#8208;TPO&#44; escores UCT basais mais baixos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Demonstra&#231;&#227;o de caracter&#237;sticas estatisticamente significantes e n&#227;o significantes por&#233;m mais frequentes&#44; observadas nos grupos de resposta ao tratamento da UCE</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabela 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">anti&#8208;TPO&#44; anticorpo antitireoide peroxidase&#59; anti&#8208;TG&#44; anticorpo antitiroglobulina&#59; ASST&#44; teste cut&#226;neo de soro aut&#243;logo&#59; BAT&#44; teste de ativa&#231;&#227;o de bas&#243;filos&#59; BHRA&#44; ensaio de libera&#231;&#227;o de histamina de bas&#243;filos&#59; PCR&#44; prote&#237;na C reativa&#59; CsA&#44; ciclosporina&#8208;A&#59; UCE&#44; urtic&#225;ria cr&#244;nica espont&#226;nea&#59; VHS&#44; velocidade de hemossedimenta&#231;&#227;o&#59; <span class="elsevierStyleItalic">H&#46; pilori</span>&#44; <span class="elsevierStyleItalic">Helicobacter pylori</span>&#59; Oma&#44; omalizumabe&#59; UCT&#44; teste de controle de urtic&#225;ria&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">O que j&#225; se sabe sobre o tema&#63;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">O que este artigo acrescenta&#63;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A autoimunidade na UCE foi classificada em mecanismos autoimunes tipo 1 &#40;tipo IgE autoal&#233;rgico&#41; e mecanismos autoimunes tipo 2b &#40;tipo IgG&#41;&#46; Esses dois tipos t&#234;m sido associados a diferentes caracter&#237;sticas cl&#237;nicas e laboratoriais e padr&#245;es de resposta ao tratamento&#46; A urtic&#225;ria autoimune tipo 1 est&#225; associada a anticorpos IgE contra autoant&#237;genos&#44; taxas mais altas de doen&#231;as al&#233;rgicas concomitantes&#44; n&#237;veis de IgE total normais ou altos e altas taxas de resposta a omalizumabe&#46; A urtic&#225;ria autoimune tipo 2b est&#225; associada a anticorpos IgG contra autoant&#237;genos&#44; positividade para BHRA&#44; BAT&#44; ASST&#44; doen&#231;a mais grave com maior dura&#231;&#227;o&#44; maiores taxas de doen&#231;as autoimunes concomitantes&#44; maiores taxas de basopenia e eosinopenia&#44; n&#237;veis mais baixos de IgE total&#44; n&#237;veis mais altos de PCR&#44; positividade de ANA mais alta&#44; baixas taxas de resposta a anti&#8208;histam&#237;nicos e omalizumabe&#44; maiores taxas de resposta &#224; terapia imunossupressora&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Foram encontrados dois tipos distintos de end&#243;tipos de UCE de acordo com seus padr&#245;es de resposta ao tratamento que s&#227;o compat&#237;veis com os dois diferentes end&#243;tipos de urtic&#225;ria autoimune&#59; os respondedores ao Oma tendem a ser mais frequentemente do sexo masculino&#44; com atividade de doen&#231;a mais baixa &#40;escores UCT basais mais altos&#41; e com taxas mais baixas de positividade no ASST&#44; taxas mais baixas de hist&#243;ria familiar&#44; n&#237;veis mais baixos de PCR&#44; taxas mais baixas de basopenia e eosinopenia&#44; n&#237;veis mais baixos de VHS&#44; menor frequ&#234;ncia de angioedema&#44; menor frequ&#234;ncia de doen&#231;a autoimune da tireoide e n&#237;veis mais elevados de IgE total&#46; Estas s&#227;o caracter&#237;sticas que foram associadas &#224; autoimunidade tipo 1 &#40;tipo IgE&#41;&#46; Os respondedores &#224; CsA apresentaram n&#237;veis mais altos de PCR e maior frequ&#234;ncia de hist&#243;ria familiar positiva&#44; ASST positivo&#44; eosinopenia&#44; basopenia&#44; n&#237;veis mais altos de VHS&#44; maior frequ&#234;ncia de positividade anti&#8208;TPO&#44; n&#237;veis mais baixos de IgE total e maior atividade da doen&#231;a &#40;escores UCT basais mais baixos&#41;&#46; Estas s&#227;o caracter&#237;sticas que foram associadas &#224; autoimunidade tipo 2b &#40;tipo IgG&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Os biomarcadores para a resposta ao Oma foram relatados como altos n&#237;veis de IgE total&#44; negatividade no ASST&#44; negatividade no BHRA&#44; falta de atividade de up&#8208;regula&#231;&#227;o de bas&#243;filos CD203c&#44; alta express&#227;o de bas&#243;filos Fc&#603;RI e n&#237;veis mais baixos de IL&#8208;31&#44; enquanto biomarcadores para resposta &#224; ciclosporina foram relatados como positividade de BHRA&#44; n&#237;veis mais altos de PCR&#44; baixos n&#237;veis de IgE total&#44; positividade no ASST&#44; baixos n&#237;veis de d&#237;mero&#8208;D&#44; alta atividade da doen&#231;a e curta dura&#231;&#227;o da doen&#231;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Os n&#227;o respondedores a nenhum dos dois medicamentos s&#227;o mais frequentemente do sexo feminino&#44; com maior atividade da doen&#231;a e com mais angioedema&#44; doen&#231;a autoimune da tireoide&#44; autoanticorpos da tireoide e positividade para <span class="elsevierStyleItalic">H&#46; pylori</span>&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">O que j&#225; se sabe sobre o tema&#44; o que este artigo acrescenta&#63;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Refer&#234;ncias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:29 [
            0 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The EAACI&#47;GA&#40;2&#41;LEN&#47;EDF&#47;WAO guideline for the definition&#44; classification&#44; diagnosis and management of urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Zuberbier"
                            1 => "W&#46; Aberer"
                            2 => "R&#46; Asero"
                            3 => "A&#46;H&#46; Abdul Latiff"
                            4 => "D&#46; Baker"
                            5 => "B&#46; Ballmer-Weber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13397"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2018"
                        "volumen" => "73"
                        "paginaInicial" => "1393"
                        "paginaFinal" => "1414"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29336054"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Looking forward to new targeted treatments for chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Kocaturk"
                            1 => "M&#46; Maurer"
                            2 => "M&#46; Metz"
                            3 => "C&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13601-016-0139-2"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Transl Allergy&#46;"
                        "fecha" => "2017"
                        "volumen" => "7"
                        "paginaInicial" => "1"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28078079"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Urticaria&#58; Collegium Internationale Allergologicum &#40;CIA&#41; Update 2020"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Maurer"
                            1 => "K&#46; Eyerich"
                            2 => "S&#46; Eyerich"
                            3 => "M&#46; Ferrer"
                            4 => "J&#46; Gutermuth"
                            5 => "K&#46; Hartmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000507218"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int Arch Allergy Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "181"
                        "paginaInicial" => "321"
                        "paginaFinal" => "333"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32224621"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutting Edge&#58; Biomarkers for Chronic Spontaneous Urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46; Folci"
                            1 => "E&#46; Heffler"
                            2 => "G&#46;W&#46; Canonica"
                            3 => "R&#46; Furlan"
                            4 => "E&#46; Brunetta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1155/2018/5615109"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Immunol Res&#46;"
                        "fecha" => "2018"
                        "volumen" => "2018"
                        "paginaInicial" => "5615109"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30584542"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46; Santiago"
                            1 => "B&#46; Ferreira"
                            2 => "L&#46; Ramos"
                            3 => "M&#46; Goncalo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.17005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "180"
                        "paginaInicial" => "199"
                        "paginaFinal" => "200"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30007073"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria&#58; A Systematic Review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Kulthanan"
                            1 => "C&#46; Subchookul"
                            2 => "S&#46; Hunnangkul"
                            3 => "L&#46; Chularojanamontri"
                            4 => "P&#46; Tuchinda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4168/aair.2019.11.5.736"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy Asthma Immunol Res&#46;"
                        "fecha" => "2019"
                        "volumen" => "11"
                        "paginaInicial" => "736"
                        "paginaFinal" => "755"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31332983"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Potential blood biomarkers in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "P&#46; Kolkhir"
                            1 => "F&#46; Andre"
                            2 => "M&#46;K&#46; Church"
                            3 => "M&#46; Maurer"
                            4 => "M&#46; Metz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cea.12870"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Allergy"
                        "fecha" => "2017"
                        "volumen" => "47"
                        "paginaInicial" => "19"
                        "paginaFinal" => "36"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27926978"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria&#58; Results of the PURIST Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46; Schoepke"
                            1 => "R&#46; Asero"
                            2 => "A&#46; Ellrich"
                            3 => "M&#46; Ferrer"
                            4 => "A&#46; Gimenez-Arnau"
                            5 => "C&#46;E&#46;H&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13949"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2019"
                        "volumen" => "74"
                        "paginaInicial" => "2427"
                        "paginaFinal" => "2436"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31228881"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomized double&#8208;blind study of cyclosporin in chronic&#8217;idiopathic&#8217; urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;E&#46; Grattan"
                            1 => "B&#46;F&#46; O&#8217;Donnell"
                            2 => "D&#46;M&#46; Francis"
                            3 => "N&#46; Niimi"
                            4 => "R&#46;J&#46; Barlow"
                            5 => "P&#46;T&#46; Seed"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1046/j.1365-2133.2000.03664.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2000"
                        "volumen" => "143"
                        "paginaInicial" => "365"
                        "paginaFinal" => "372"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10951147"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A positive serum basophil histamine release assay is a marker for ciclosporin&#8208;responsiveness in patients with chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Iqbal"
                            1 => "K&#46; Bhargava"
                            2 => "P&#46;S&#46; Skov"
                            3 => "S&#46; Falkencrone"
                            4 => "C&#46;E&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/2045-7022-2-19"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Transl Allergy&#46;"
                        "fecha" => "2012"
                        "volumen" => "2"
                        "paginaInicial" => "19"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23025508"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors that predict the success of cyclosporine treatment for chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46;M&#46; Hollander"
                            1 => "S&#46;S&#46; Joo"
                            2 => "H&#46;J&#46; Wedner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2011.08.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma Immunol&#46;"
                        "fecha" => "2011"
                        "volumen" => "107"
                        "paginaInicial" => "523"
                        "paginaFinal" => "528"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22123382"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Response to oral cyclosporine therapy and high sensitivity&#8208;CRP level in chronic idiopathic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "T&#46; Ohtsuka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-4632.2010.04384.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Dermatol&#46;"
                        "fecha" => "2010"
                        "volumen" => "49"
                        "paginaInicial" => "579"
                        "paginaFinal" => "584"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20534097"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria&#58; Real&#8208;life data"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Salman"
                            1 => "G&#46; Demir"
                            2 => "N&#46; Bekiroglu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.12975"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther"
                        "fecha" => "2019"
                        "volumen" => "32"
                        "paginaInicial" => "e12975"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31145524"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Ertas"
                            1 => "K&#46; Ozyurt"
                            2 => "M&#46; Atasoy"
                            3 => "T&#46; Hawro"
                            4 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13345"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy"
                        "fecha" => "2018"
                        "volumen" => "73"
                        "paginaInicial" => "705"
                        "paginaFinal" => "712"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29083482"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;D&#46; Straesser"
                            1 => "E&#46; Oliver"
                            2 => "T&#46; Palacios"
                            3 => "T&#46; Kyin"
                            4 => "J&#46; Patrie"
                            5 => "L&#46; Borish"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2017.10.030"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2018"
                        "volumen" => "6"
                        "paginaInicial" => "1386"
                        "paginaFinal" => "1388"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29175369"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors related to omalizumab resistance in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Magen"
                            1 => "T&#46; Chikovani"
                            2 => "D&#46;A&#46; Waitman"
                            3 => "N&#46;R&#46; Kahan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2500/aap.2019.40.4230"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy Asthma Proc&#46;"
                        "fecha" => "2019"
                        "volumen" => "40"
                        "paginaInicial" => "273"
                        "paginaFinal" => "278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31262381"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Basophil FcepsilonRI Expression in Chronic Spontaneous Urticaria&#58; A Potential Immunological Predictor of Response to Omalizumab Therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Deza"
                            1 => "M&#46; Bertolin-Colilla"
                            2 => "R&#46;M&#46; Pujol"
                            3 => "L&#46; Curto-Barredo"
                            4 => "D&#46; Soto"
                            5 => "M&#46; Garcia"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2340/00015555-2654"
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Derm Venereol&#46;"
                        "fecha" => "2017"
                        "volumen" => "97"
                        "paginaInicial" => "698"
                        "paginaFinal" => "704"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28303277"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eosinopenia&#44; in Chronic Spontaneous Urticaria&#44; Is Associated with High Disease Activity&#44; Autoimmunity&#44; and Poor Response to Treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Kolkhir"
                            1 => "M&#46;K&#46; Church"
                            2 => "S&#46; Altrichter"
                            3 => "P&#46;S&#46; Skov"
                            4 => "T&#46; Hawro"
                            5 => "S&#46; Frischbutter"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2019.08.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "318"
                        "paginaFinal" => "325"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31472293"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cyclosporine and omalizumab together&#58; A new option for chronic refractory urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46; Sanchez"
                            1 => "L&#46; Alvarez"
                            2 => "R&#46; Cardona"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2020.02.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "2101"
                        "paginaFinal" => "2103"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32112923"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Concomitant treatment with omalizumab and cyclosporine for chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46;D&#46; Rosenblum"
                            1 => "S&#46; Nassau"
                            2 => "L&#46; Fonacier"
                            3 => "S&#46;L&#46; Mawhirt"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2020.04.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma&#46; Immunol"
                        "fecha" => "2020"
                        "volumen" => "125"
                        "paginaInicial" => "111"
                        "paginaFinal" => "112"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32360694"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Combination therapy with omalizumab and an immune&#8208;suppressive agent for resistant chronic spontaneous rrticaria &#8208; A real&#8208;life experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "R&#46; Maoz-Segal"
                            1 => "T&#46; Levy"
                            2 => "S&#46; Haj-Yahia"
                            3 => "I&#46; Offengenden"
                            4 => "M&#46; Iancovich-Kidon"
                            5 => "N&#46; Agmon-Levin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.waojou.2020.100448"
                      "Revista" => array:5 [
                        "tituloSerie" => "World Allergy Organ J&#46;"
                        "fecha" => "2020"
                        "volumen" => "13"
                        "paginaInicial" => "100448"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32774663"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Co&#8208;occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "R&#46; Asero"
                            1 => "A&#46;V&#46; Marzano"
                            2 => "S&#46; Ferrucci"
                            3 => "M&#46; Lorini"
                            4 => "V&#46; Carbonelli"
                            5 => "M&#46; Cugno"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cei.13428"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Exp Immunol"
                        "fecha" => "2020"
                        "volumen" => "200"
                        "numero" => "3"
                        "paginaInicial" => "242"
                        "paginaFinal" => "249"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32115683"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Etiologic aspects and prognostic factors of patients with chronic urticaria&#58; nonrandomized&#44; prospective&#44; descriptive study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Gregoriou"
                            1 => "D&#46; Rigopoulos"
                            2 => "A&#46; Katsambas"
                            3 => "A&#46; Katsarou"
                            4 => "D&#46; Papaioannou"
                            5 => "A&#46; Gkouvi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2310/7750.2008.08035"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Cutan Med Surg"
                        "fecha" => "2009"
                        "volumen" => "13"
                        "numero" => "4"
                        "paginaInicial" => "198"
                        "paginaFinal" => "203"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19706227"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#91;Epidemiologic features in patients with antihistamine&#8208;resistant chronic urticaria&#93;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46;S&#46; Borges"
                            1 => "S&#46; Tassinari"
                            2 => "A&#46; Flores"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Alerg Mex&#46;"
                        "fecha" => "2015"
                        "volumen" => "62"
                        "paginaInicial" => "279"
                        "paginaFinal" => "286"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26556663"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Grieco"
                            1 => "L&#46; Dies"
                            2 => "A&#46; Sernicola"
                            3 => "C&#46; Chello"
                            4 => "N&#46; Gagliostro"
                            5 => "G&#46; Carnicelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2217/imt-2020-0088"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunotherapy&#46;"
                        "fecha" => "2020"
                        "volumen" => "12"
                        "paginaInicial" => "1173"
                        "paginaFinal" => "1181"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32892673"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria Patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Kocaturk"
                            1 => "G&#46; Deza"
                            2 => "K&#46; Kiziltac"
                            3 => "A&#46;M&#46; Gimenez-Arnau"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000491530"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int Arch Allergy Immunol&#46;"
                        "fecha" => "2018"
                        "volumen" => "177"
                        "paginaInicial" => "360"
                        "paginaFinal" => "364"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30130798"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Urticaria and Angioedema Across the Ages"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Saini"
                            1 => "M&#46; Shams"
                            2 => "J&#46;A&#46; Bernstein"
                            3 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2020.03.030"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "1866"
                        "paginaFinal" => "1874"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32298850"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biomarkers In Chronic Spontaneous Urticaria&#58; Current Targets And Clinical Implications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "I&#46; Puxeddu"
                            1 => "F&#46; Petrelli"
                            2 => "F&#46; Angelotti"
                            3 => "C&#46; Croia"
                            4 => "P&#46; Migliorini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/JAA.S184986"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Asthma Allergy&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "285"
                        "paginaFinal" => "295"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31571935"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New treatments for chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "P&#46; Kolkhir"
                            1 => "S&#46; Altrichter"
                            2 => "M&#46; Munoz"
                            3 => "T&#46; Hawro"
                            4 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2019.08.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "124"
                        "paginaInicial" => "2"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31446134"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "pt"
  "url" => "/26662752/0000009700000005/v1_202209080628/S2666275222001849/v1_202209080628/pt/main.assets"
  "Apartado" => array:4 [
    "identificador" => "89618"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Artigo Original"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/26662752/0000009700000005/v1_202209080628/S2666275222001849/v1_202209080628/pt/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001849?idApp=UINPBA00008Z"
]
Compartilhar
Informação da revista

Estatísticas

Siga este link para acessar o texto completo do artigo

Artigo original
Omalizumabe versus ciclosporina‐A para o tratamento da urticária crônica espontânea: podemos definir endótipos com melhor resposta?
Emek Kocatürka,
Autor para correspondência
ekocaturk@ku.edu.tr

Autor para correspondência.
, Emel Bülbül Başkanb, Özlem Su Küçükc, Mustafa Özdemird, Sinem Örneke, Pelin Kuteyla Canf, Eda Haşalb, Burhan Enging, Nilgün Atakanh, Erkan Alpsoyi
a Departamento de Dermatologia, Koc University, Escola de Medicina, Istambul, Turquia
b Departamento de Dermatologia, Uludag University, Escola de Medicina, Bursa, Turquia
c Departamento de Dermatologia, Bezmialem Vakif University, Escola de Medicina, Istambul, Turquia
d Departamento de Dermatologia, Istanbul Medipol University, Escola de Medicina, Istambul, Turquia
e Departamento de Dermatologia, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turquia
f Departamento de Dermatologia, VM Medical Park Maltepe Hospital, Istambul, Turquia
g Departamento de Dermatologia, Istanbul University, Escola de MedicinaCerrahpasa, Istanbul, Turquia
h Departamento de Dermatologia, Hacettepe University, Escola de Medicina, Ankara, Turquia
i Departamento de Dermatologia, Akdeniz University, Escola de Medicina, Antalya, Turquia
Ver más
Lido
6382
Vezes
que se leu este artigo
1853
Total PDF
4529
Total HTML
Compartilhar estatísticas
 array:23 [
  "pii" => "S2666275222001849"
  "issn" => "26662752"
  "doi" => "10.1016/j.abdp.2022.07.027"
  "estado" => "S300"
  "fechaPublicacion" => "2022-09-01"
  "aid" => "600"
  "copyrightAnyo" => "2022"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by/4.0/"
  "subdocumento" => "fla"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:18 [
      "pii" => "S0365059622001386"
      "issn" => "03650596"
      "doi" => "10.1016/j.abd.2022.03.003"
      "estado" => "S300"
      "fechaPublicacion" => "2022-09-01"
      "aid" => "600"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by/4.0/"
      "subdocumento" => "fla"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>"
        "titulo" => "Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria&#58; can we define better-responding endotypes&#63;"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "592"
            "paginaFinal" => "600"
          ]
        ]
        "contieneResumen" => array:1 [
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig0005"
            "etiqueta" => "Figure 1"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr1.jpeg"
                "Alto" => 1672
                "Ancho" => 1675
                "Tamanyo" => 199167
              ]
            ]
            "detalles" => array:1 [
              0 => array:3 [
                "identificador" => "at0005"
                "detalle" => "Figure "
                "rol" => "short"
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">The distribution of four types of treatment responses&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Emek Kocat&#252;rk, Emel B&#252;lb&#252;l Ba&#351;kan, &#214;zlem Su K&#252;&#231;&#252;k, Mustafa &#214;zdemir, Sinem &#214;rnek, Pelin Kuteyla Can, Eda Ha&#351;al, Burhan Engin, Nilg&#252;n Atakan, Erkan Alpsoy"
            "autores" => array:10 [
              0 => array:2 [
                "nombre" => "Emek"
                "apellidos" => "Kocat&#252;rk"
              ]
              1 => array:2 [
                "nombre" => "Emel B&#252;lb&#252;l"
                "apellidos" => "Ba&#351;kan"
              ]
              2 => array:2 [
                "nombre" => "&#214;zlem Su"
                "apellidos" => "K&#252;&#231;&#252;k"
              ]
              3 => array:2 [
                "nombre" => "Mustafa"
                "apellidos" => "&#214;zdemir"
              ]
              4 => array:2 [
                "nombre" => "Sinem"
                "apellidos" => "&#214;rnek"
              ]
              5 => array:2 [
                "nombre" => "Pelin Kuteyla"
                "apellidos" => "Can"
              ]
              6 => array:2 [
                "nombre" => "Eda"
                "apellidos" => "Ha&#351;al"
              ]
              7 => array:2 [
                "nombre" => "Burhan"
                "apellidos" => "Engin"
              ]
              8 => array:2 [
                "nombre" => "Nilg&#252;n"
                "apellidos" => "Atakan"
              ]
              9 => array:2 [
                "nombre" => "Erkan"
                "apellidos" => "Alpsoy"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "pt" => array:9 [
          "pii" => "S2666275222001849"
          "doi" => "10.1016/j.abdp.2022.07.027"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "pt"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001849?idApp=UINPBA00008Z"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622001386?idApp=UINPBA00008Z"
      "url" => "/03650596/0000009700000005/v1_202208290604/S0365059622001386/v1_202208290604/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S2666275222001412"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2022.07.004"
    "estado" => "S300"
    "fechaPublicacion" => "2022-09-01"
    "aid" => "574"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Artigo original</span>"
      "titulo" => "Fatores preditivos da espessura do melanoma"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "tieneResumen" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "601"
          "paginaFinal" => "605"
        ]
      ]
      "contieneResumen" => array:1 [
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Rita Carreiro Silva, Ricardo Jos&#233; David Costa Vieira"
          "autores" => array:2 [
            0 => array:2 [
              "nombre" => "Ana Rita Carreiro"
              "apellidos" => "Silva"
            ]
            1 => array:2 [
              "nombre" => "Ricardo Jos&#233; David Costa"
              "apellidos" => "Vieira"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S036505962200112X"
        "doi" => "10.1016/j.abd.2021.12.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S036505962200112X?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001412?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009700000005/v1_202209080628/S2666275222001412/v1_202209080628/pt/main.assets"
  ]
  "itemAnterior" => array:19 [
    "pii" => "S2666275222001552"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2022.07.017"
    "estado" => "S300"
    "fechaPublicacion" => "2022-09-01"
    "aid" => "590"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by/4.0/"
    "subdocumento" => "fla"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Artigo original</span>"
      "titulo" => "O uso da t&#233;cnica de avalia&#231;&#227;o intraoperat&#243;ria de margens cir&#250;rgicas por congela&#231;&#227;o &#8220;<span class="elsevierStyleItalic">en face&#8221;</span> no manejo de carcinomas cut&#226;neos&#58; resultados oncol&#243;gicos de uma &#250;nica institui&#231;&#227;o"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "tieneResumen" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "583"
          "paginaFinal" => "591"
        ]
      ]
      "contieneResumen" => array:1 [
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1830
              "Ancho" => 2925
              "Tamanyo" => 377531
            ]
          ]
          "descripcion" => array:1 [
            "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Aspecto cl&#237;nico da les&#227;o antes da excis&#227;o com delimita&#231;&#227;o dermatosc&#243;pica das margens cir&#250;rgicas&#46; &#40;B&#41; Amostra ressecada e identificada com fio cir&#250;rgico pelo cirurgi&#227;o do ponto de refer&#234;ncia do paciente de 12 horas&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Ana Carolina Vasconcellos Guedes Otsuka, Eduardo Bertolli, Mariana Petaccia de Macedo, Clovis Antonio Lopes Pinto, Jo&#227;o Pedreira Duprat Neto"
          "autores" => array:5 [
            0 => array:2 [
              "nombre" => "Ana Carolina Vasconcellos Guedes"
              "apellidos" => "Otsuka"
            ]
            1 => array:2 [
              "nombre" => "Eduardo"
              "apellidos" => "Bertolli"
            ]
            2 => array:2 [
              "nombre" => "Mariana Petaccia de"
              "apellidos" => "Macedo"
            ]
            3 => array:2 [
              "nombre" => "Clovis Antonio Lopes"
              "apellidos" => "Pinto"
            ]
            4 => array:2 [
              "nombre" => "Jo&#227;o Pedreira Duprat"
              "apellidos" => "Neto"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0365059622001283"
        "doi" => "10.1016/j.abd.2021.09.013"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059622001283?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001552?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009700000005/v1_202209080628/S2666275222001552/v1_202209080628/pt/main.assets"
  ]
  "pt" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Artigo original</span>"
    "titulo" => "Omalizumabe <span class="elsevierStyleItalic">versus</span> ciclosporina&#8208;A para o tratamento da urtic&#225;ria cr&#244;nica espont&#226;nea&#58; podemos definir end&#243;tipos com melhor resposta&#63;"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "592"
        "paginaFinal" => "600"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Emek Kocat&#252;rk, Emel B&#252;lb&#252;l Ba&#351;kan, &#214;zlem Su K&#252;&#231;&#252;k, Mustafa &#214;zdemir, Sinem &#214;rnek, Pelin Kuteyla Can, Eda Ha&#351;al, Burhan Engin, Nilg&#252;n Atakan, Erkan Alpsoy"
        "autores" => array:10 [
          0 => array:4 [
            "nombre" => "Emek"
            "apellidos" => "Kocat&#252;rk"
            "email" => array:1 [
              0 => "ekocaturk@ku.edu.tr"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Emel B&#252;lb&#252;l"
            "apellidos" => "Ba&#351;kan"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "&#214;zlem Su"
            "apellidos" => "K&#252;&#231;&#252;k"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "Mustafa"
            "apellidos" => "&#214;zdemir"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "Sinem"
            "apellidos" => "&#214;rnek"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "Pelin Kuteyla"
            "apellidos" => "Can"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "Eda"
            "apellidos" => "Ha&#351;al"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "Burhan"
            "apellidos" => "Engin"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
            ]
          ]
          8 => array:3 [
            "nombre" => "Nilg&#252;n"
            "apellidos" => "Atakan"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
          9 => array:3 [
            "nombre" => "Erkan"
            "apellidos" => "Alpsoy"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">i</span>"
                "identificador" => "aff0045"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:9 [
          0 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Koc University&#44; Escola de Medicina&#44; Istambul&#44; Turquia"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Uludag University&#44; Escola de Medicina&#44; Bursa&#44; Turquia"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Bezmialem Vakif University&#44; Escola de Medicina&#44; Istambul&#44; Turquia"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Istanbul Medipol University&#44; Escola de Medicina&#44; Istambul&#44; Turquia"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Ankara Diskapi Yildirim Beyazit Training and Research Hospital&#44; Ankara&#44; Turquia"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; VM Medical Park Maltepe Hospital&#44; Istambul&#44; Turquia"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Istanbul University&#44; Escola de MedicinaCerrahpasa&#44; Istanbul&#44; Turquia"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Hacettepe University&#44; Escola de Medicina&#44; Ankara&#44; Turquia"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
          8 => array:3 [
            "entidad" => "Departamento de Dermatologia&#44; Akdeniz University&#44; Escola de Medicina&#44; Antalya&#44; Turquia"
            "etiqueta" => "i"
            "identificador" => "aff0045"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspond&#234;ncia&#46;"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1672
            "Ancho" => 1675
            "Tamanyo" => 197262
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Distribui&#231;&#227;o dos quatro tipos de respostas ao tratamento da UCE&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Introdu&#231;&#227;o</span><p id="par0005" class="elsevierStylePara elsevierViewall">A urtic&#225;ria cr&#244;nica espont&#226;nea &#40;UCE&#41; &#233; definida como urticas e&#47;ou angioedema por mais de seis semanas&#46; A principal c&#233;lula efetora na fisiopatologia da doen&#231;a &#233; o mast&#243;cito&#44; que sofre degranula&#231;&#227;o ap&#243;s est&#237;mulo&#44; principalmente via Fc&#603;R1 de alta afinidade e leva &#224; libera&#231;&#227;o de v&#225;rios mediadores e resulta no recrutamento de c&#233;lulas como bas&#243;filos&#44; eosin&#243;filos e linf&#243;citos T&#46;<a class="elsevierStyleCrossRefs" href="#bib0150"><span class="elsevierStyleSup">1&#44;2</span></a> &#201; amplamente aceito que mecanismos autoimunes desempenham papel importante na ativa&#231;&#227;o dos mast&#243;citos&#46; Na UCE&#44; postulam&#8208;se dois tipos de autoimunidade&#58; 1&#41; autoimunidade tipo I &#40;tamb&#233;m chamada de autoalergia&#41;&#44; na qual participam autoanticorpos IgE e 2&#41; autoimunidade tipo IIb&#44; na qual autoanticorpos IgG contra autoant&#237;genos ativam receptores de mast&#243;citos&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">3</span></a> As <span class="elsevierStyleItalic">International Urticaria Guidelines</span> recomendam omalizumabe &#40;Oma&#41; como tratamento de primeira linha na UCE resistente aos anti&#8208;histam&#237;nicos &#40;pacientes que n&#227;o respondem a doses quatro vezes maiores de anti&#8208;histam&#237;nicos H1&#41;&#44; enquanto ciclosporina&#8208;A &#40;CsA&#41; &#233; recomendada para pacientes que apresentam falha no tratamento com Oma&#46; Embora esse algoritmo gradativo tenha sido adotado&#44; ele pode ser demorado&#44; caro e pode n&#227;o ser adequado para todos os pacientes com UCE&#46;<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">1</span></a> J&#225; houve tentativas de encontrar biomarcadores ou caracter&#237;sticas cl&#237;nicas que definam a resposta ao tratamento em pacientes com UCE&#44; e o teste de soro aut&#243;logo&#44; ensaio de libera&#231;&#227;o de histamina de bas&#243;filos &#40;BHRA&#41;&#44; n&#237;veis totais de IgE&#44; <span class="elsevierStyleSmallCaps">d</span>&#8208;d&#237;mero e PCR s&#227;o alguns dos biomarcadores que foram identificados como associados &#224; resposta ao tratamento com Oma ou CsA&#46;<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">4</span></a> Entretanto&#44; muitos dos estudos realizados para determinar biomarcadores concentraram&#8208;se em um determinado medicamento&#44; neste caso Oma ou CsA&#44; mas faltam estudos comparando respondedores ao Oma com respondedores &#224; CsA&#46; O objetivo do presente estudo foi determinar se caracter&#237;sticas espec&#237;ficas dos pacientes ou marcadores laboratoriais poderiam ser utilizados como indicadores de resposta ao Oma ou &#224; CsA em pacientes com UCE&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">M&#233;todos</span><p id="par0010" class="elsevierStylePara elsevierViewall">Foram analisados retrospectivamente os arquivos de pacientes de sete centros da Turquia &#40;Okmeydani Training and Research Hospital&#44; Istanbul&#59; Uludag University&#44; School of Medicine&#44; Bursa&#59; Bezmialem Vakif University&#44; School of Medicine&#44; Istanbul&#59; Istanbul Medipol University&#44; School of Medicine&#44; Istanbul&#59; Istanbul University&#44; Cerrahpasa School of Medicine&#44; Istanbul&#59; Hacettepe University&#44; School of Medicine&#44; Ankara&#59; Akdeniz University&#44; School of Medicine&#44; Antalya&#41; com experi&#234;ncia no tratamento de pacientes com UCE&#46; O diagn&#243;stico de UCE foi realizado com base no exame f&#237;sico e na hist&#243;ria do paciente&#46; Os pacientes foram considerados resistentes aos anti&#8208;histam&#237;nicos quando n&#227;o responderam a doses quatro vezes maiores de anti&#8208;histam&#237;nicos H1&#46; Os crit&#233;rios de inclus&#227;o para pacientes com UCE foram&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">1&#46;</span><p id="par0015" class="elsevierStylePara elsevierViewall">Ter UCE por mais de seis semanas&#59;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">2&#46;</span><p id="par0020" class="elsevierStylePara elsevierViewall">Ser maior de 18 anos&#59;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">3&#46;</span><p id="par0025" class="elsevierStylePara elsevierViewall">N&#227;o estar gr&#225;vida ou amamentando&#59;</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">4&#46;</span><p id="par0030" class="elsevierStylePara elsevierViewall">Ter sido submetido a uma tentativa de tratamento com Oma e CsA &#40;n&#227;o simultaneamente&#41; durante o curso da doen&#231;a por pelo menos tr&#234;s meses para decidir se houve resposta ao tratamento ou n&#227;o&#59;</p></li><li class="elsevierStyleListItem" id="lsti0025"><span class="elsevierStyleLabel">5&#46;</span><p id="par0035" class="elsevierStylePara elsevierViewall">Incluir os escores do teste de controle de urtic&#225;ria &#40;UCT&#44; do ingl&#234;s <span class="elsevierStyleItalic">urticaria control test</span>&#41; e haver dados cl&#237;nicos e laboratoriais suficientes nos arquivos&#46;</p></li></ul></p><p id="par0040" class="elsevierStylePara elsevierViewall">Os crit&#233;rios de exclus&#227;o foram&#58;<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0030"><span class="elsevierStyleLabel">1&#46;</span><p id="par0045" class="elsevierStylePara elsevierViewall">Urtic&#225;ria cr&#244;nica induzida&#59;</p></li><li class="elsevierStyleListItem" id="lsti0035"><span class="elsevierStyleLabel">2&#46;</span><p id="par0050" class="elsevierStylePara elsevierViewall">Pacientes menores de 18 anos&#59;</p></li><li class="elsevierStyleListItem" id="lsti0040"><span class="elsevierStyleLabel">3&#46;</span><p id="par0055" class="elsevierStylePara elsevierViewall">Tratamento com CsA e Oma simultaneamente&#46;</p></li></ul></p><p id="par0060" class="elsevierStylePara elsevierViewall">A resposta ao tratamento foi definida pelos escores do UCT &#40;UCT &#8805; 12&#44; sob controle&#41;&#46; Quatro grupos de pacientes foram definidos de acordo com as respostas ao tratamento&#58;<ul class="elsevierStyleList" id="lis0015"><li class="elsevierStyleListItem" id="lsti0045"><span class="elsevierStyleLabel">1&#46;</span><p id="par0065" class="elsevierStylePara elsevierViewall">Pacientes que respondem apenas ao Oma &#40;n&#227;o respondem &#224; CsA&#41; &#8211; Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59;</p></li><li class="elsevierStyleListItem" id="lsti0050"><span class="elsevierStyleLabel">2&#46;</span><p id="par0070" class="elsevierStylePara elsevierViewall">Pacientes que respondem apenas &#224; CsA &#40;n&#227;o respondem ao Oma&#41; &#8211; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59;</p></li><li class="elsevierStyleListItem" id="lsti0055"><span class="elsevierStyleLabel">3&#46;</span><p id="par0075" class="elsevierStylePara elsevierViewall">Pacientes que respondem ao Oma e &#224; CsA &#8211; Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59;</p></li><li class="elsevierStyleListItem" id="lsti0060"><span class="elsevierStyleLabel">4&#46;</span><p id="par0080" class="elsevierStylePara elsevierViewall">Pacientes que n&#227;o respondem a nenhum dos medicamentos &#40;Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span>&#41;&#46;</p></li></ul></p><p id="par0085" class="elsevierStylePara elsevierViewall">Foi realizada compara&#231;&#227;o entre todos os grupos de resposta em rela&#231;&#227;o &#224;s caracter&#237;sticas como idade&#44; sexo&#44; hist&#243;ria familiar&#44; presen&#231;a de angioedema&#44; dura&#231;&#227;o da doen&#231;a&#44; urtic&#225;ria induzida &#40;UI&#41;&#44; escores UCT basais e marcadores laboratoriais&#44; como o teste cut&#226;neo com soro aut&#243;logo &#40;ASST&#44; <span class="elsevierStyleItalic">autologous serum skin test</span>&#41;&#44; n&#237;veis altos de PCR&#44; VHS&#44; eosinopenia&#44; basopenia&#44; n&#237;veis baixos de IgE total&#44; presen&#231;a de doen&#231;a autoimune da tireoide&#44; bem como positividade para anticorpo antiperoxidase tireoidiana &#40;anti&#8208;TPO&#41; e antitireoglobulina &#40;anti&#8208;TG&#41;&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">A aprova&#231;&#227;o &#233;tica foi obtida do Comit&#234; de &#201;tica do centro coordenador do Okmeydani Training and Research Hospital &#40;23&#47;05&#47;2017&#59; n&#250;mero 98&#8208;667&#41;&#46;</p><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Defini&#231;&#245;es</span><p id="par0095" class="elsevierStylePara elsevierViewall">Altos n&#237;veis de PCR&#58; &#8805; 5<span class="elsevierStyleHsp" style=""></span>mg&#47;L&#59;</p><p id="par0100" class="elsevierStylePara elsevierViewall">Altos n&#237;veis de VHS&#58; &#8805; 20<span class="elsevierStyleHsp" style=""></span>mm&#47;h&#59;</p><p id="par0105" class="elsevierStylePara elsevierViewall">Basopenia &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;01 &#215; 109&#47;L&#59;</p><p id="par0110" class="elsevierStylePara elsevierViewall">Eosinopenia &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05 &#215; 109&#47;L&#59;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Baixos n&#237;veis de IgE total&#44; &#60;<span class="elsevierStyleHsp" style=""></span>43 UI&#47;mL&#59;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Doen&#231;a autoimune da tireoide &#40;AIT&#41;&#58; diagn&#243;stico estabelecido de AIT encontrado nos arquivos dos pacientes &#40;n&#227;o apenas da positividade ao anti&#8208;TPO&#47;anti&#8208;TG&#41;&#59;</p><p id="par0125" class="elsevierStylePara elsevierViewall">Alta atividade de doen&#231;a UCT &#60;<span class="elsevierStyleHsp" style=""></span>6&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">An&#225;lise estat&#237;stica</span><p id="par0130" class="elsevierStylePara elsevierViewall">As caracter&#237;sticas basais foram descritas como m&#233;dias e desvios&#8208;padr&#227;o &#40;DP&#41; para vari&#225;veis cont&#237;nuas e frequ&#234;ncias e porcentagens para vari&#225;veis categ&#243;ricas&#46; O teste Qui&#8208;Quadrado de Pearson e o teste exato de Fisher foram usados para compara&#231;&#227;o de grupos de vari&#225;veis categ&#243;ricas&#46; O teste U de Mann&#8208;Whitney foi utilizado para as compara&#231;&#245;es das vari&#225;veis cont&#237;nuas entre os grupos&#46; Acredita&#8208;se que somente um n&#237;vel baixo de IgE pode ser considerado tendo uma associa&#231;&#227;o com os resultados do tratamento com CsA<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">5</span></a> que confundiria as associa&#231;&#245;es apresentadas em artigos anteriores&#44; embora n&#227;o esteja totalmente confirmada&#46; Portanto&#44; foram utilizados modelos de regress&#227;o log&#237;stica multinomial para calcular ORs ajustados para n&#237;veis baixos &#40;&#60; 43&#41; de IgE &#40;aAORs&#41; para examinar as associa&#231;&#245;es entre os resultados do tratamento com CsA para UCE&#46; Os valores bilaterais de p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05 foram considerados estatisticamente significantes&#46;</p></span></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Resultados</span><p id="par0135" class="elsevierStylePara elsevierViewall">Foram inclu&#237;dos 110 prontu&#225;rios de pacientes com UCE de sete centros &#40;74 mulheres &#91;67&#44;3&#37;&#93;&#44; com m&#233;dia de idade de 40&#44;98<span class="elsevierStyleHsp" style=""></span>&#177; 12&#44;37&#59; varia&#231;&#227;o&#58; 16&#8208;81 anos&#44; e dura&#231;&#227;o m&#233;dia da doen&#231;a de 57&#44;21<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>69&#44;31 meses&#59; varia&#231;&#227;o&#58; 6&#8208;402 meses&#41;&#46; As caracter&#237;sticas demogr&#225;ficas dos pacientes s&#227;o apresentadas na <a class="elsevierStyleCrossRef" href="#tbl0005">tabela 1</a>&#46; Quatro tipos de respostas ao tratamento foram assim distribu&#237;dos&#58; 47 &#40;42&#44;7&#37;&#41; Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; 15 &#40;13&#44;6&#37;&#41; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; 24 &#40;21&#44;8&#37;&#41; Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> e 24 &#40;21&#44;8&#37;&#41; Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46; Os achados laboratoriais dos pacientes s&#227;o apresentados na <a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a>&#46; Diferen&#231;as estatisticamente significantes&#44; bem como caracter&#237;sticas estatisticamente n&#227;o significantes&#44; por&#233;m mais frequentes&#44; s&#227;o apresentadas na <a class="elsevierStyleCrossRef" href="#tbl0015">tabela 3</a>&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">N&#227;o h&#225; diferen&#231;as significantes entre Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span> e CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; mas algumas caracter&#237;sticas s&#227;o mais prevalentes no grupo CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span></span><p id="par0140" class="elsevierStylePara elsevierViewall">Quando foi feita a compara&#231;&#227;o entre os pacientes que responderam apenas ao Oma &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>47&#41; e apenas &#224; CsA &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&#41;&#44; n&#227;o houve diferen&#231;as estatisticamente significantes entre os grupos quanto aos par&#226;metros cl&#237;nicos e laboratoriais&#46; Mas o ASST positivo &#40;52&#44;8&#37; <span class="elsevierStyleItalic">vs</span>&#46; 71&#44;4&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;47&#41;&#44; hist&#243;ria familiar positiva &#40;4&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 20&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;086&#41;&#44; n&#237;veis elevados de PCR &#40;42&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 72&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;074&#41;&#44; basopenia &#40;2&#44;2&#37; <span class="elsevierStyleItalic">vs</span>&#46; 16&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;10&#41;&#44; eosinopenia &#40;0 <span class="elsevierStyleItalic">vs</span>&#46; 20&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;08&#41;&#44; altos n&#237;veis de VHS &#40;34&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 61&#44;5&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;07&#41;&#44; baixos n&#237;veis de IgE total &#40;20&#44;9&#37; <span class="elsevierStyleItalic">vs</span>&#46; 41&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;259&#41;&#44; positividade para anti&#8208;TPO &#40;37&#44;9&#37; <span class="elsevierStyleItalic">vs</span>&#46; 50&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;69&#41; e escores UCT basais mais baixos &#40;6 <span class="elsevierStyleItalic">vs</span>&#46; 3&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;122&#41; foram mais frequentes no grupo CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; mesmo que as diferen&#231;as n&#227;o tenham sido estatisticamente significantes&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Respondedores ao Oma t&#234;m escores UCT de linha basal mais altos em compara&#231;&#227;o com os n&#227;o respondedores ao Oma</span><p id="par0145" class="elsevierStylePara elsevierViewall">Quando o grupo Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span> &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>47&#41; foi comparado com o Oma&#8722;resp<span class="elsevierStyleSup">&#8722;</span> &#40;Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> e CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59; n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>39&#41;&#44; o &#250;nico par&#226;metro estatisticamente significante foi o escore UCT inicial&#44; o qual foi 6 <span class="elsevierStyleItalic">vs</span>&#46; 4&#44;5 em Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span><span class="elsevierStyleItalic">vs</span>&#46; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> e Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span>&#44; respectivamente &#40;p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;045&#41;&#46; Outras caracter&#237;sticas que foram observadas sem signific&#226;ncia estat&#237;stica no grupo Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span> foram maior taxa de pacientes do sexo masculino &#40;38&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 23&#44;1&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;13&#41;&#44; menor propor&#231;&#227;o de positividade no ASST &#40;52&#44;8&#37; <span class="elsevierStyleItalic">vs</span>&#46; 62&#44;5&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;45&#41;&#44; menor propor&#231;&#227;o de hist&#243;ria familiar &#40;4&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 15&#44;4&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;13&#41;&#44; menor frequ&#234;ncia de PCR alta &#40;42&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 55&#44;2&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;29&#41;&#44; menor frequ&#234;ncia de eosinopenia &#40;0&#37; <span class="elsevierStyleItalic">vs</span>&#46; 13&#44;6&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;10&#41;&#44; menor frequ&#234;ncia de basopenia &#40;2&#44;2&#37; <span class="elsevierStyleItalic">vs</span>&#46; 9&#44;4&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;30&#41;&#44; menor frequ&#234;ncia de altos n&#237;veis de VHS &#40;34&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 44&#44;1&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;36&#41;&#44; menor frequ&#234;ncia de angioedema &#40;57&#44;4&#37; <span class="elsevierStyleItalic">vs</span>&#46; 69&#44;2&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;26&#41;&#44; menor frequ&#234;ncia de doen&#231;a autoimune da tireoide &#40;22&#44;9&#37; <span class="elsevierStyleItalic">vs</span>&#46; 26&#44;9&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;71&#41; e maior frequ&#234;ncia de IgE total<span class="elsevierStyleHsp" style=""></span>&#62; 43 &#40;79&#44;1&#37; <span class="elsevierStyleItalic">vs</span>&#46; 66&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;22&#41;&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">N&#237;veis elevados de PCR s&#227;o mais frequentes em respondedores &#224; CsA em compara&#231;&#227;o com n&#227;o respondedores &#224; CsA</span><p id="par0150" class="elsevierStylePara elsevierViewall">A &#250;nica diferen&#231;a estatisticamente significante entre CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&#41; e CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> &#40;Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span>&#44; Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span> e Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#59; n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>95&#41; foram altos n&#237;veis de PCR&#44; o que foi mais frequente em CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> &#40;72&#44;7&#37; <span class="elsevierStyleItalic">vs</span>&#46; 40&#44;3&#37;&#59; OR<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>3&#44;96&#44; IC 95&#37; 0&#44;97&#8208;16&#44;1&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;05&#41; e ter altos n&#237;veis de PCR aumentou a chance de resposta favor&#225;vel ao tratamento com CsA em 6&#44;1 ap&#243;s ajuste para n&#237;veis baixos de IgE total &#40;ORa<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>6&#44;1&#59; IC 95&#37; 1&#44;17&#8208;31&#44;8&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;032&#41;&#46;</p><p id="par0155" class="elsevierStylePara elsevierViewall">Hist&#243;ria familiar positiva &#40;20&#37; <span class="elsevierStyleItalic">vs</span>&#46; 8&#44;4&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;172&#41;&#44; ASST positivo &#40;71&#44;4&#37; <span class="elsevierStyleItalic">vs</span>&#46; 55&#44;7&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;692&#41;&#44; eosinopenia &#40;20&#37; <span class="elsevierStyleItalic">vs</span>&#46; 2&#44;3&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;085&#41;&#44; basopenia &#40;16&#44;7&#37; <span class="elsevierStyleItalic">vs</span>&#46; 2&#44;2&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;067&#41;&#44; altos n&#237;veis de VHS &#40;61&#44;5&#37; <span class="elsevierStyleItalic">vs</span>&#46; 36&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;08&#41;&#44; n&#237;veis mais baixos de IgE total &#40;41&#44;7&#37; <span class="elsevierStyleItalic">vs</span>&#46; 22&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;159&#41;&#44; positividade anti&#8208;TPO &#40;50&#37; <span class="elsevierStyleItalic">vs</span>&#46; 32&#44;8&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;436&#41;&#44; escores UCT basais mais baixos &#40;3 <span class="elsevierStyleItalic">vs</span>&#46; 7&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;107&#41; foram mais frequentes&#44; embora sem signific&#226;ncia estat&#237;stica&#44; no grupo CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#46;</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Sexo feminino e escore UCT de linha basal mais baixo foram mais frequentes em n&#227;o respondedores a qualquer um dos dois medicamentos</span><p id="par0160" class="elsevierStylePara elsevierViewall">Os n&#227;o respondedores a qualquer um dos dois medicamentos foram comparados com os grupos respondedores &#40;Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> e Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#41; e a compara&#231;&#227;o revelou que a maioria dos Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> era do sexo feminino &#40;21&#59; 87&#44;5&#37; <span class="elsevierStyleItalic">vs</span>&#46; 53&#59; 61&#44;6&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;017&#41; e o escore UCT basal foi menor em Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span> &#40;5 <span class="elsevierStyleItalic">vs</span>&#46; 7&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;06&#41;&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Respondedores a ambos os medicamentos tiveram menos angioedema e escore UCT basal mais alto</span><p id="par0165" class="elsevierStylePara elsevierViewall">O grupo Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> foi comparado com o restante dos pacientes &#40;Oma&#8722;resp<span class="elsevierStyleSup">&#43;</span>&#44; CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> e Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#8722;</span>&#41;&#46; A frequ&#234;ncia de angioedema foi menor &#40;8&#59; 33&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 54&#59; 62&#44;8&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;01&#41; e o escore UCT de linha basal foi maior no grupo Oma&#8722;CsA&#8722;resp<span class="elsevierStyleSup">&#43;</span> &#40;8 <span class="elsevierStyleItalic">vs</span>&#46; 5&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;017&#41;&#46;</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Discuss&#227;o</span><p id="par0170" class="elsevierStylePara elsevierViewall">O presente estudo mostrou que&#44; em uma subpopula&#231;&#227;o de pacientes com UCE refrat&#225;ria aos anti&#8208;histam&#237;nicos que receberam Oma e CsA em algum momento durante o seguimento&#44; a maioria &#40;40&#37;&#41; respondeu ao Oma&#44; a minoria &#40;10&#37;&#41; respondeu &#224; CsA&#44; enquanto 20&#37; responderam a ambos&#44; e outros 20&#37; n&#227;o responderam a nenhum dos dois medicamentos &#40;resumo dos achados na <a class="elsevierStyleCrossRef" href="#tbl0020">tabela 4</a>&#41;&#46; Esses achados s&#227;o interessantes em virtude dos relatos de altas taxas de resposta de pacientes com UCE ao tratamento com CsA&#44; que variaram de 38 a 100&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0175"><span class="elsevierStyleSup">6</span></a> Seria esperado que mais pacientes respondessem ao tratamento com CsA&#59; entretanto&#44; ap&#243;s um exame cuidadoso dos achados cl&#237;nicos e laboratoriais da popula&#231;&#227;o de pacientes do presente estudo&#44; verificou&#8208;se que 65&#37; da popula&#231;&#227;o de pacientes tinha n&#237;veis elevados de IgE total &#40;&#62; 100 UI&#47;mL&#41;&#44;o que foi relatado como uma caracter&#237;stica da UCE autoimune tipo I e um fator desfavor&#225;vel para a resposta ao tratamento com CsA&#46;<a class="elsevierStyleCrossRefs" href="#bib0160"><span class="elsevierStyleSup">3&#44;5</span></a> Maurer et al&#46;<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">3</span></a> descreveram algumas caracter&#237;sticas da UCE autoimune tipo I <span class="elsevierStyleItalic">versus</span> tipo IIb e apontaram que a presen&#231;a de auto&#8208;IgE &#40;p&#46; ex&#46;&#44; contra TPO&#44; IL&#8208;24&#44; ds&#8208;DNA&#41;&#44; taxas mais altas de doen&#231;as al&#233;rgicas concomitantes&#44; n&#237;veis de IgE total normais ou elevados e alta taxa de resposta ao Oma favorecem a UCE autoimune tipo I&#44; enquanto a presen&#231;a de auto&#8208;IgG &#40;contra IgE&#44; Fc&#603;RI&#41;&#44; maior atividade da doen&#231;a&#44; maior dura&#231;&#227;o da doen&#231;a&#44; maiores taxas de doen&#231;as autoimunes concomitantes&#44; menores n&#237;veis de IgE total&#44; maiores taxas de eosinopenia e basopenia&#44; n&#237;veis mais elevados de PCR&#44; maiores taxas de positividade para ANA&#44; indicam baixa taxa de resposta ou resposta mais lenta ao Oma e boa resposta ao tratamento imunossupressor&#46; Com base nessa classifica&#231;&#227;o de end&#243;tipo&#44; &#233; poss&#237;vel explicar por que a taxa de resposta &#224; CsA &#233; baixa nessa popula&#231;&#227;o de pacientes&#59; acredita&#8208;se na baixa frequ&#234;ncia de pacientes com eosinopenia&#44; basopenia&#44; baixos n&#237;veis de IgE&#44; altos n&#237;veis de PCR e alta gravidade da doen&#231;a&#59; mas a alta frequ&#234;ncia de pacientes com altos n&#237;veis de IgE total mostra que a maioria dessa popula&#231;&#227;o de pacientes &#233; composta por UCE autoimune tipo I e&#44; portanto&#44; mais propensa a responder ao tratamento com Oma&#46;</p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0175" class="elsevierStylePara elsevierViewall">A busca por biomarcadores que possam predizer a resposta a um determinado tratamento tem sido um assunto de interesse e muitas publica&#231;&#245;es relataram que alguns biomarcadores podem ser &#250;teis na determina&#231;&#227;o da resposta a certos tratamentos na UCE&#46; Para o Oma&#44; altos n&#237;veis de IgE&#44; negatividade no ASST&#44; negatividade de BHRA&#44; a falta de atividade de up&#8208;regula&#231;&#227;o de bas&#243;filos CD203c&#44; alta express&#227;o de bas&#243;filos Fc&#603;RI e n&#237;veis mais baixos de IL&#8208;31 foram relatados como biomarcadores para boa resposta ao tratamento&#44; enquanto para ciclosporina&#44; positividade de BHRA&#44; n&#237;veis mais altos de PCR&#44; n&#237;veis baixos de IgE&#44; positividade no ASST&#44; n&#237;veis baixos de d&#237;mero&#8208;<span class="elsevierStyleSmallCaps">D</span>&#44; alta atividade da doen&#231;a e curta dura&#231;&#227;o da doen&#231;a foram indicativos de boa resposta ao tratamento&#46;<a class="elsevierStyleCrossRefs" href="#bib0165"><span class="elsevierStyleSup">4&#44;7</span></a> Na popula&#231;&#227;o do presente estudo&#44; n&#227;o houve diferen&#231;a estatisticamente significante entre os respondedores ao Oma e CsA em rela&#231;&#227;o aos par&#226;metros de compara&#231;&#227;o&#44; mas isso pode ter sido em virtude da distribui&#231;&#227;o desequilibrada de pacientes com determinados par&#226;metros&#46; Como mencionado anteriormente&#44; havia um percentual menor de pacientes com boa resposta ao tratamento com CsA&#44; o que pode ter resultado em limita&#231;&#227;o da an&#225;lise estat&#237;stica&#59; isso se deve principalmente &#224; escolha do Oma como tratamento de primeira linha em pacientes refrat&#225;rios aos anti&#8208;histam&#237;nicos&#46; A compara&#231;&#227;o entre os grupos mostrou que ASST positivo&#44; hist&#243;ria familiar positiva&#44; altos n&#237;veis de PCR&#44; basopenia&#44; eosinopenia&#44; altos n&#237;veis de VHS&#44; baixos n&#237;veis de IgE total&#44; positividade anti&#8208;TPO e escores UCT basais mais baixos foram mais frequentes em respondedores &#224; CsA do que respondedores ao Oma&#46; Esses achados referem&#8208;se novamente &#224; import&#226;ncia dos end&#243;tipos de UCE&#59; os par&#226;metros mencionados associados &#224; resposta &#224; CsA tamb&#233;m s&#227;o caracter&#237;sticas da UCE autoimune do tipo IIb&#46; A urtic&#225;ria autoimune tipo IIb &#233; definida por autoanticorpos IgG anti&#8208;IgE ou Fc&#603;RI&#44; teste de ativa&#231;&#227;o de bas&#243;filos &#40;BAT&#44; <span class="elsevierStyleItalic">basophil activation test</span>&#41; positivo e um ASST positivo e demonstrou responder melhor ao tratamento com CsA&#46;<a class="elsevierStyleCrossRefs" href="#bib0185"><span class="elsevierStyleSup">8&#8211;11</span></a> Tamb&#233;m foi demonstrado que pacientes com n&#237;veis elevados de PCR responderam melhor &#224; CsA&#44; o que &#233; um achado relatado em estudos anteriores&#46;<a class="elsevierStyleCrossRef" href="#bib0205"><span class="elsevierStyleSup">12</span></a> Al&#233;m disso&#44; foi observado que n&#237;veis baixos de IgE total foram mais frequentes em respondedores &#224; CsA&#44; como relatado por Santiago et al&#46;<a class="elsevierStyleCrossRef" href="#bib0170"><span class="elsevierStyleSup">5</span></a> Semelhante aos achados de Hollander et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0200"><span class="elsevierStyleSup">11</span></a> que relataram que a gravidade inicial mais alta predizia uma resposta bem&#8208;sucedida ao tratamento com CsA&#44; os respondedores &#224; CsA no presente estudo tinham escores UCT mais baixos&#46; Embora os respondedores &#224; CsA no presente estudo tivessem apresentado maior frequ&#234;ncia de positividade de ASST&#44; a evid&#234;ncia de ASST ser um potencial preditor de resposta ao tratamento com CsA n&#227;o foi conclusiva&#46;</p><p id="par0180" class="elsevierStylePara elsevierViewall">Observou&#8208;se que os respondedores ao Oma nessa popula&#231;&#227;o estudada apresentavam escore UCT basal significantemente mais alto do que os n&#227;o respondedores ao Oma&#44; o que indicou atividade de doen&#231;a menor&#46; Esse fato tamb&#233;m foi relatado por Salman et al&#46;<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">13</span></a> A presen&#231;a de angioedema&#44;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">14</span></a> sexo feminino&#44;<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">15</span></a> n&#237;veis elevados de PCR&#44;<a class="elsevierStyleCrossRef" href="#bib0225"><span class="elsevierStyleSup">16</span></a> positividade de ASST&#44;<a class="elsevierStyleCrossRef" href="#bib0230"><span class="elsevierStyleSup">17</span></a> eosinopenia e basopenia<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">18</span></a> estiveram associadas &#224; resposta insatisfat&#243;ria ao Oma&#46; N&#237;veis s&#233;ricos mais altos de IgE total s&#227;o atualmente aceitos como biomarcador estabelecido da resposta ao Oma&#44;<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">14</span></a> embora n&#227;o tenha sido estatisticamente significante no presente estudo&#46;</p><p id="par0185" class="elsevierStylePara elsevierViewall">Um em cada cinco pacientes do presente estudo apresentou resposta a ambos os medicamentos&#44; e esses pacientes apresentaram menos angioedema e escores UCT basais mais altos &#40;menor atividade basal da doen&#231;a&#41;&#44; que s&#227;o caracter&#237;sticas de menor atividade da doen&#231;a&#46; Uma resposta favor&#225;vel ao tratamento &#233; prevista em pacientes com menor atividade da doen&#231;a&#59; entretanto&#44; seria esclarecedor se fosse poss&#237;vel realizar testes para autoanticorpos IgE e IgG e determinar que tipo de autoimunidade esses pacientes t&#234;m&#46; Dessa maneira&#44; a hip&#243;tese de que esses pacientes podem ter ambos os tipos de autoanticorpos e&#44; portanto&#44; ambos os tipos de autoimunidade poderia ser considerada&#46; A ideia da presen&#231;a de tais pacientes vem das observa&#231;&#245;es de relatos crescentes de pacientes que respondem ao tratamento conjunto com Oma e CsA&#46; Mas os pacientes nesses relatos n&#227;o parecem responder ao tratamento com Oma ou CsA isoladamente&#44; mas ao tratamento com um regime combinado&#44; refletindo pacientes com alta atividade da doen&#231;a e possivelmente com dois tipos de autoimunidade&#46;<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">19&#8211;21</span></a> A exist&#234;ncia conjunta de dois tipos de autoimunidade foi demonstrada em um estudo cl&#237;nico recente de Asero et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">22</span></a> que mostraram a coexist&#234;ncia de autoanticorpos IgE e IgG para receptores IgE de alta e baixa afinidade &#40;Fc&#603;RI e Fc&#603;RII&#41;&#44; fator tecidual e tireoglobulina&#44; principalmente em respondedores tardios ao Oma&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">Vinte por cento dos pacientes neste estudo n&#227;o responderam ao tratamento com Oma ou CsA&#46; Essa popula&#231;&#227;o de pacientes refrat&#225;rios incluiu mais mulheres e mais pacientes com escores UCT de linha basal mais baixos&#46; Essas caracter&#237;sticas tamb&#233;m foram associadas &#224; doen&#231;a refrat&#225;ria em relatos anteriores&#59; o sexo feminino foi relatado como sendo um preditor de maior tempo at&#233; a remiss&#227;o&#44;<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">23</span></a> resist&#234;ncia aos anti&#8208;histam&#237;nicos<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">24</span></a> e maior frequ&#234;ncia de recorr&#234;ncia ap&#243;s o tratamento com Oma&#46;<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">25</span></a> Escores de UCT basais mais baixos foram associados &#224; taxa de resposta mais baixa e maior necessidade de aumento da dose de Oma&#46;<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">26</span></a> Apesar de n&#227;o ter signific&#226;ncia estat&#237;stica&#44; os pacientes refrat&#225;rios apresentaram maior taxa de positividade para <span class="elsevierStyleItalic">H&#46; pylori</span>&#44; embora n&#227;o haja informa&#231;&#245;es sobre as taxas de erradica&#231;&#227;o do <span class="elsevierStyleItalic">H&#46; pylori</span> nesses pacientes&#46; Isso enfatiza a import&#226;ncia de avaliar e tratar comorbidades em pacientes com UCE&#46;</p><p id="par0195" class="elsevierStylePara elsevierViewall">O &#250;nico estudo que se assemelha em alguns aspectos ao presente trabalho &#233; o publicado por S&#225;nchez et al&#46;&#44; em que relataram que&#44; de 88 pacientes em seu estudo&#44; 26&#47;88 &#40;29&#44;5&#37;&#41; responderam &#224; CsA&#44; 41&#47;88 &#40;46&#44;5&#37;&#41; responderam ao Oma&#44; 16&#47;88 &#40;18&#44;2&#37;&#41; responderam quando CsA e Oma foram combinados e apenas cinco &#40;5&#44;6&#37;&#41; pacientes permaneceram sem resposta ao tratamento&#46;<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">19</span></a> As taxas de resposta ao Oma foram semelhantes &#224;s do presente estudo e tamb&#233;m foram semelhantes &#224; taxa de resposta completa relatada pelos ensaios cl&#237;nicos e estudos da pr&#225;tica cl&#237;nica do Oma&#44; que &#233; de aproximadamente 40 a 50&#37;&#46;<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">27</span></a> Contudo&#44; a taxa de n&#227;o respondedores a ambos os medicamentos parece ser muito menor do que no presente estudo&#44; o que pode ser atribu&#237;do &#224; prefer&#234;ncia do &#250;ltimo de n&#227;o incluir pacientes que utilizaram Oma e CsA ao mesmo tempo&#46; Se esses pacientes refrat&#225;rios fossem tratados com ambos os medicamentos&#44; a taxa de n&#227;o respondedores poderia ter sido menor&#46;</p><p id="par0200" class="elsevierStylePara elsevierViewall">A raz&#227;o pela qual esses pacientes n&#227;o respondem nem ao Oma nem &#224; CsA precisa ser explorada em estudos prospectivos maiores&#44; que avaliem o perfil dos pacientes com exames laboratoriais detalhados&#44; incluindo autoanticorpos tipo IgG e IgE&#44; testes BAT&#47;BHRA&#44; bem como outros mediadores inflamat&#243;rios&#44; tanto na pele quanto no sangue perif&#233;rico&#46; Esses pacientes podem ter um mecanismo patol&#243;gico subjacente diferente&#44; incluindo envolvimento de componentes do complemento&#44; infiltrados na pele compostos por eosin&#243;filos ou linf&#243;citos T produzindo outras citoquinas inflamat&#243;rias&#44; como IL&#8208;4&#44; IL&#8208;5&#44; IL&#8208;23&#44; IL&#8208;17 ou IL&#8208;31&#44; ou outros mecanismos&#44; incluindo angiog&#234;nese&#44; coagula&#231;&#227;o e desregula&#231;&#227;o vascular&#46;<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">28</span></a> H&#225; muitas varia&#231;&#245;es diferentes de op&#231;&#245;es terap&#234;uticas para esse grupo de pacientes refrat&#225;rios que est&#227;o sendo utilizados em ensaios cl&#237;nicos em progresso ou sob desenvolvimento&#44; incluindo dupilumabe&#44; fenebrutinibe&#44; benralizumabe e anti&#8208;siglec&#8208;8&#46;<a class="elsevierStyleCrossRefs" href="#bib0155"><span class="elsevierStyleSup">2&#44;29</span></a></p><p id="par0205" class="elsevierStylePara elsevierViewall">As limita&#231;&#245;es do presente estudo compreendem a sua natureza retrospectiva&#44; que n&#227;o incluiu o mesmo n&#250;mero de pacientes nos quatro grupos delineados&#44; n&#227;o incluindo pacientes que foram tratados tanto com CsA quanto com Oma&#44; um baixo n&#250;mero de pacientes&#44; a falta de um grupo controle e a falta de testes BAT ou BHRA&#46; A natureza transversal do estudo levou a uma popula&#231;&#227;o de estudo que pode n&#227;o refletir a popula&#231;&#227;o geral com UCE&#44; mas a natureza multic&#234;ntrica do estudo pode ter atenuado esse efeito&#46;</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conclus&#227;o</span><p id="par0210" class="elsevierStylePara elsevierViewall">A categoriza&#231;&#227;o de pacientes em end&#243;tipos pode ser &#250;til para prever as respostas ao tratamento e pode ajudar na escolha da op&#231;&#227;o mais adequada de tratamento para cada paciente com UCE&#46; Para o melhor cuidado dos pacientes&#44; determinar a atividade da doen&#231;a na linha basal e orientar a avalia&#231;&#227;o e o manejo de comorbidades s&#227;o de grande import&#226;ncia&#46;</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Suporte financeiro</span><p id="par0215" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Contribui&#231;&#227;o dos autores</span><p id="par0220" class="elsevierStylePara elsevierViewall">Emek Kocaturk&#58; Contribui&#231;&#245;es substanciais para a concep&#231;&#227;o e planejamento do estudo&#59; Obten&#231;&#227;o&#44; an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica da literatura&#59; Participa&#231;&#227;o na reda&#231;&#227;o do manuscrito&#59; escrita do manuscrito&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0225" class="elsevierStylePara elsevierViewall">Emel B&#252;lb&#252;l Ba&#351;kan&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0230" class="elsevierStylePara elsevierViewall">&#214;zlem Su K&#252;&#231;&#252;k&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">Mustafa &#214;zdemir&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Sinem &#214;rnek&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Participa&#231;&#227;o efetiva na orienta&#231;&#227;o da pesquisa&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0245" class="elsevierStylePara elsevierViewall">Pelin Kuteyla Can&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Participa&#231;&#227;o efetiva na orienta&#231;&#227;o da pesquisa&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0250" class="elsevierStylePara elsevierViewall">Eda Ha&#351;al&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Participa&#231;&#227;o efetiva na orienta&#231;&#227;o da pesquisa&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0255" class="elsevierStylePara elsevierViewall">Burhan Engin&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0260" class="elsevierStylePara elsevierViewall">Nilg&#252;n Atakan&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0265" class="elsevierStylePara elsevierViewall">Erkan Alpsoy&#58; Obten&#231;&#227;o dos dados&#44; ou an&#225;lise e interpreta&#231;&#227;o dos dados&#59; Revis&#227;o cr&#237;tica de conte&#250;do intelectual importante&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Conflito de interesses</span><p id="par0270" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres1767850"
          "titulo" => "Resumo"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Fundamentos"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Objetivo"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "M&#233;todos"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Resultados"
            ]
            4 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Limita&#231;&#245;es do estudo"
            ]
            5 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "Conclus&#245;es"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1554162"
          "titulo" => "Palavras&#8208;chave"
        ]
        2 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introdu&#231;&#227;o"
        ]
        3 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "M&#233;todos"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Defini&#231;&#245;es"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "An&#225;lise estat&#237;stica"
            ]
          ]
        ]
        4 => array:3 [
          "identificador" => "sec0025"
          "titulo" => "Resultados"
          "secciones" => array:5 [
            0 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "N&#227;o h&#225; diferen&#231;as significantes entre Oma&#8722;resp e CsA&#8722;resp&#44; mas algumas caracter&#237;sticas s&#227;o mais prevalentes no grupo CsA&#8722;resp"
            ]
            1 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "Respondedores ao Oma t&#234;m escores UCT de linha basal mais altos em compara&#231;&#227;o com os n&#227;o respondedores ao Oma"
            ]
            2 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "N&#237;veis elevados de PCR s&#227;o mais frequentes em respondedores &#224; CsA em compara&#231;&#227;o com n&#227;o respondedores &#224; CsA"
            ]
            3 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "Sexo feminino e escore UCT de linha basal mais baixo foram mais frequentes em n&#227;o respondedores a qualquer um dos dois medicamentos"
            ]
            4 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Respondedores a ambos os medicamentos tiveram menos angioedema e escore UCT basal mais alto"
            ]
          ]
        ]
        5 => array:2 [
          "identificador" => "sec0055"
          "titulo" => "Discuss&#227;o"
        ]
        6 => array:2 [
          "identificador" => "sec0060"
          "titulo" => "Conclus&#227;o"
        ]
        7 => array:2 [
          "identificador" => "sec0065"
          "titulo" => "Suporte financeiro"
        ]
        8 => array:2 [
          "identificador" => "sec0070"
          "titulo" => "Contribui&#231;&#227;o dos autores"
        ]
        9 => array:2 [
          "identificador" => "sec0075"
          "titulo" => "Conflito de interesses"
        ]
        10 => array:1 [
          "titulo" => "Refer&#234;ncias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-01-05"
    "fechaAceptado" => "2022-03-07"
    "PalabrasClave" => array:1 [
      "pt" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palavras&#8208;chave"
          "identificador" => "xpalclavsec1554162"
          "palabras" => array:4 [
            0 => "Biomarcadores"
            1 => "Ciclosporina"
            2 => "Omalizumabe"
            3 => "Urtic&#225;ria cr&#244;nica"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "pt" => array:3 [
        "titulo" => "Resumo"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Fundamentos</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A urtic&#225;ria cr&#244;nica espont&#226;nea &#40;UCE&#41; &#233; caracterizada por urticas e&#47;ou angioedema recorrentes por mais de seis semanas&#46; As diretrizes recomendam omalizumabe &#40;Oma&#41; como tratamento de primeira linha e ciclosporina&#8208;A &#40;CsA&#41; como tratamento de segunda linha em UCE resistentes aos anti&#8208;histam&#237;nicos&#46; Esse algoritmo gradativo pode ser demorado e caro&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objetivo</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Determinar indicadores de resposta ao Oma ou &#224; CsA em pacientes com UCE&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">M&#233;todos</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Foram analisados retrospectivamente dados de sete centros da Turquia&#59; os crit&#233;rios de inclus&#227;o para os pacientes foram receber tratamento com Oma e CsA &#40;n&#227;o simultaneamente&#41; em algum momento durante o seguimento&#46; As caracter&#237;sticas cl&#237;nicas e laboratoriais foram analisadas e comparadas entre os grupos&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Resultados</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">De 110 pacientes com UCE&#44; 47 &#40;42&#44;7&#37;&#41; responderam ao Oma&#44; 15 &#40;13&#44;6&#37;&#41; responderam &#224; CsA&#44; 24 &#40;21&#44;8&#37;&#41; responderam ao Oma e &#224; CsA e 24 &#40;21&#44;8&#37;&#41; n&#227;o responderam a nenhum dos dois medicamentos&#46; N&#237;veis elevados de PCR foram mais frequentes em respondedores &#224; CsA &#40;72&#44;7&#37; <span class="elsevierStyleItalic">vs</span>&#46; 40&#44;3&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;055&#41;&#46; Os respondedores ao Oma tiveram escores ao teste de controle da urtic&#225;ria &#40;UCT&#41; basais mais altos &#40;6 <span class="elsevierStyleItalic">vs</span>&#46; 4&#44;5&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;045&#41;&#46; Os respondedores a ambos os medicamentos tiveram menos angioedema e escores UCT basais mais altos em compara&#231;&#227;o com outros grupos &#40;33&#44;3&#37; <span class="elsevierStyleItalic">vs</span>&#46; 62&#44;8&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;01 e 8 <span class="elsevierStyleItalic">vs</span>&#46; 5&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;017&#41;&#46; Os n&#227;o&#8208;respondedores a ambos os medicamentos apresentaram maior frequ&#234;ncia no sexo feminino e escores UCT basais mais baixos em compara&#231;&#227;o aos outros grupos &#40;87&#44;5&#37; <span class="elsevierStyleItalic">vs</span>&#46; 61&#44;6&#37;&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;017 e 5 <span class="elsevierStyleItalic">vs</span>&#46; 7&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;06&#41;&#46;</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Limita&#231;&#245;es do estudo</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Natureza retrospectiva&#44; n&#227;o haver n&#250;meros iguais de pacientes em cada grupo&#44; n&#250;mero limitado de pacientes&#44; nenhum grupo controle&#44; falta de teste de ativa&#231;&#227;o de bas&#243;filos &#40;BAT&#41; ou teste de BHRA &#40;ensaio de libera&#231;&#227;o de histamina de bas&#243;filos&#41;&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Conclus&#245;es</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">A avalia&#231;&#227;o basal da atividade da doen&#231;a&#44; que considera a presen&#231;a de angioedema e escores de atividade da doen&#231;a&#44; sexo e n&#237;veis de PCR&#44; pode ser &#250;til para prever os resultados do tratamento em pacientes com UCE e escolher o tratamento mais adequado para cada paciente&#46; A categoriza&#231;&#227;o de pacientes em end&#243;tipos espec&#237;ficos pode otimizar e aumentar o sucesso do tratamento&#46;</p></span>"
        "secciones" => array:6 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Fundamentos"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Objetivo"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "M&#233;todos"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Resultados"
          ]
          4 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Limita&#231;&#245;es do estudo"
          ]
          5 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "Conclus&#245;es"
          ]
        ]
      ]
    ]
    "NotaPie" => array:2 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Como citar este artigo&#58; Kocat&#252;rk E&#44; Ba&#351;kan EB&#44; K&#252;&#231;&#252;k OS&#44; &#214;zdemir M&#44; &#214;rnek S&#44; Can PK&#44; et al&#46; Omalizumab versus cyclosporin&#8208;A for the treatment of chronic spontaneous urticaria&#58; can we define better&#8208;responding endotypes&#63; An Bras Dermatol&#46; 2022&#59;97&#58;592&#8211;600&#46;</p>"
      ]
      1 => array:2 [
        "etiqueta" => "&#9734;&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Trabalho realizado no Departamento de Dermatologia&#44; Koc University&#44; Escola de Medicina&#44; Istambul&#44; Turquia&#59; Departamento de Dermatologia&#44; Uludag University&#44; Escola de Medicina&#44; Bursa&#44; Turquia&#59; Departamento de Dermatologia&#44; Bezmialem Vakif University&#44; Escola de Medicina&#44; Istambul&#44; Turquia&#59; Departamento de Dermatologia&#44; Istanbul Medipol University&#44; Escola de Medicina&#44; Istambul&#44; Turquia&#59; Departamento de Dermatologia&#44; Ankara Diskapi Yildirim Beyazit Training and Research Hospital&#44; Ankara&#44; Turquia&#59; Departamento de Dermatologia&#44; VM Medical Park Maltepe Hospital&#44; Istanbul&#44; Turquia&#59; Departamento de Dermatologia&#44; Istanbul University&#44; Escola de Medicina Cerrahpasa&#44; Istanbul&#44; Turquia&#59; Departamento de Dermatologia&#44; Hacettepe University&#44; Escola de Medicina&#44; Ankara&#44; Turquia&#59; Departamento de Dermatologia&#44; Akdeniz University&#44; Escola de Medicina&#44; Antalya&#44; Turquia&#46;</p>"
      ]
    ]
    "multimedia" => array:5 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1672
            "Ancho" => 1675
            "Tamanyo" => 197262
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Distribui&#231;&#227;o dos quatro tipos de respostas ao tratamento da UCE&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabela 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">UCI&#44; urtic&#225;ria cr&#244;nica induzida&#59; UCT&#44; teste de controle da urtic&#225;ria&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Par&#226;metros cl&#237;nicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>110&#44; &#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor ao omalizumabe &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>47&#44; 42&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor &#224; ciclosporina &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&#44; 13&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor a ambos&#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&#44;21&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#227;o respondedor &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&#44; 21&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Idade em anos</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#237;n&#8208;M&#225;x &#40;Mediana&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&#8208;81 &#40;39&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#8208;81 &#40;42&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&#8208;73 &#40;37&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21&#8208;66 &#40;34&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&#8208;69 &#40;37&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#233;dia<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#44;98<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#44;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">43&#44;32<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>10&#44;67&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#44;20<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>16&#44;52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&#44;79<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#44;18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#44;08<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>12&#44;64&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Sexo n &#40;&#37;&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Masculino&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36 &#40;32&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;38&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;40&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;37&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#44;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Feminino&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">74 &#40;67&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29 &#40;61&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;60&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;62&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;87&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Acompanhado de UCI n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">21 &#40;21&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;20&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;17&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Dura&#231;&#227;o da doen&#231;a &#40;meses&#41;</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#237;n&#8208;M&#225;x &#40;Mediana&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8208;402 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8208;300 &#40;30&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#8208;120 &#40;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8208;264 &#40;25&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#8208;402 &#40;36&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#233;dia<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57&#44;21<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>69&#44;31&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">60&#44;32<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>71&#44;26&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45&#44;53<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>38&#44;33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&#44;46<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>63&#44;72&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">64&#44;17<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>86&#44;37&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Angioedema&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">62 &#40;56&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27 &#40;57&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;66&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;70&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UCT basal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#237;n&#8208;M&#225;x &#40;Mediana&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8208;16 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#8208;16 &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#8208;9 &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#8208;16 &#40;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#8208;11 &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>M&#233;dia<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>4&#44;34&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#44;44<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>4&#44;65&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#44;75<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;06&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#44;12<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#44;11<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;53&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UCT &#8805; 6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46 &#40;55&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;56&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;37&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;81&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;38&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>UCT &#60;<span class="elsevierStyleHsp" style=""></span>6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37 &#40;44&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;43&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;62&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;18&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;61&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hist&#243;ria familiar positiva&#44; n &#40;&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;10&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;4&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;12&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Caracter&#237;sticas demogr&#225;ficas e cl&#237;nico-laboratoriais dos pacientes</p>"
        ]
      ]
      2 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabela 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">anti&#8208;TG&#44; anticorpo antitireoglobulina&#59; anti&#8208;TPO&#44; anticorpos antiperoxidase&#59; PCR&#44; prote&#237;na C reativa&#59; VHS&#44; velocidade de hemossedimenta&#231;&#227;o&#59; <span class="elsevierStyleItalic">H&#46; pylori</span>&#44; <span class="elsevierStyleItalic">Helicobacter pylori</span>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Achado laboratorial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>1100&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor ao omalizumabe&#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>47&#44; 42&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor &#224; ciclosporina &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&#44; 13&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Respondedor a ambos &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&#44; 21&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#227;o respondedor &#40;n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&#44; 21&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altos n&#237;veis de PCR</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>88&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">39 &#40;44&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16 &#40;42&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;72&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;44&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altos n&#237;veis de VHS</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>44&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>13&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">39 &#40;39&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">15 &#40;34&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;61&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;42&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Eosinopenia</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>23&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>10&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;5&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;20&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;8&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Basopenia</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>102&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>24&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;3&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;2&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;16&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positividade no ASST</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>77&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>36&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44 &#40;57&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">19 &#40;52&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;71&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;58&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">10 &#40;58&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#237;veis s&#233;ricos totais de IgE &#40;IU&#47;mL&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;03&#8208;6350 &#40;167&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#44;28&#8208;6350 &#40;169&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#44;03&#8208;1282 &#40;280&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#44;43&#8208;1606 &#40;150&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9&#8208;1434 &#40;172&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">370&#44;65<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>727&#44;22&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">476&#44;35<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1000&#44;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">343&#44;27<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>392&#44;27&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">252&#44;58<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>368&#44;81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">271&#44;05<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>328&#44;70&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#237;veis s&#233;ricos totais de IgE &#60;<span class="elsevierStyleHsp" style=""></span>43 &#40;IU&#47;mL&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>94&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>18&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>21&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23 &#40;24&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">9 &#40;20&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;41&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;16&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;28&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doen&#231;a autoimune da tireoide</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>35&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>9&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17 &#40;21&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;22&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;22&#44;2&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;10&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;29&#44;4&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altos n&#237;veis de anticorpo anti&#8208;TPO&#44; n &#40;&#37;&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>72&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>29&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">25 &#40;34&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11 &#40;37&#44;9&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;50&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;21&#44;1&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6 &#40;37&#44;5&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altos n&#237;veis de anticorpo anti&#8208;TG&#44; n &#40;&#37;&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>66&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>25&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>14&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18 &#40;27&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8 &#40;32&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2 &#40;25&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3 &#40;15&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5 &#40;35&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ant&#237;geno para <span class="elsevierStyleItalic">H&#46; pylori</span> positivo nas fezes&#44; n &#40;&#37;&#41;</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>87&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>19&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">n<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>15&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31 &#40;35&#44;6&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">13 &#40;31&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4 &#40;33&#44;3&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;36&#44;8&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 &#40;46&#44;7&#37;&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Achados laboratoriais dos pacientes em cada grupo</p>"
        ]
      ]
      3 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabela 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">anti&#8208;TPO&#44; anticorpo antitireoide peroxidase&#59; anti&#8208;TG&#44; anticorpo antitireoglobulina&#59; ASST&#44; teste cut&#226;neo com soro aut&#243;logo&#59; PCR&#44; prote&#237;na C reativa&#59; CsA&#44; ciclosporina&#8208;A&#59; VHS&#44; velocidade de hemossedimenta&#231;&#227;o&#59; <span class="elsevierStyleItalic">H&#46; pilori</span>&#44; <span class="elsevierStyleItalic">Helicobacter pylori</span>&#59; Oma&#44; omalizumabe&#59; UCT&#44; teste de controle de urtic&#225;ria&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Grupo tratamento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">p<span class="elsevierStyleHsp" style=""></span>&#62; 0&#44;05&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores ao Oma &#40;somente&#41; <span class="elsevierStyleItalic">vs</span>&#46; respondedores &#224; CsA &#40;somente&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nenhum&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; ASST positivo&#44; hist&#243;ria familiar positiva&#44; PCR alta&#44; basopenia&#44; eosinopenia&#44; VHS alta&#44; n&#237;veis baixos de IgE total&#44; positividade para anti&#8208;TPO&#44; escores UCT basais mais baixos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores ao Oma <span class="elsevierStyleItalic">vs</span>&#46; n&#227;o respondedores ao Oma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais alto em respondedores ao Oma&#58; escore UCT basal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequentes em respondedores ao Oma&#58; sexo masculino&#44; menores taxas de positividade para ASST&#44; menores taxas de hist&#243;ria familiar&#44; menor frequ&#234;ncia de PCR alta&#44; menor frequ&#234;ncia de eosinopenia&#44; menor frequ&#234;ncia de basopenia&#44; menor frequ&#234;ncia de altos n&#237;veis de VHS&#44; menor frequ&#234;ncia de angioedema&#44; menor frequ&#234;ncia de doen&#231;a autoimune da tireoide&#44; maior frequ&#234;ncia de n&#237;veis totais de IgE<span class="elsevierStyleHsp" style=""></span>&#62; 43&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores &#224; CsA <span class="elsevierStyleItalic">vs</span>&#46; n&#227;o respondedores &#224; CsA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; Altos n&#237;veis de PCR&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; hist&#243;ria familiar positiva&#44; ASST positivo&#44; eosinopenia&#44; basopenia&#44; altos n&#237;veis de VHS&#44; n&#237;veis mais baixos de IgE total&#44; positividade anti&#8208;TPO&#44; escores UCT basais mais baixos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores a ambos os medicamentos <span class="elsevierStyleItalic">vs</span>&#46; outros tr&#234;s grupos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores a ambos os medicamentos&#58; menor frequ&#234;ncia de angioedema&#44; maior UCT basal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Menos frequente em respondedores a ambos os medicamentos&#58; PCR alta&#44; eosinopenia&#44; basopenia&#44; doen&#231;a autoimune da tireoide&#44; positividade para anti&#8208;TPO&#44; positividade para anti&#8208;TG&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#227;o respondedores a ambos os medicamentos <span class="elsevierStyleItalic">vs</span>&#46; outros tr&#234;s grupos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Maior frequ&#234;ncia em n&#227;o respondedores&#58; sexo feminino&#44; UCT basal inferior&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Maior frequ&#234;ncia em n&#227;o respondedores&#58; Angioedema&#44; doen&#231;a autoimune da tireoide&#44; positividade anti&#8208;TG&#44; <span class="elsevierStyleItalic">H&#46; pylori</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Respondedores &#224; CsA versus n&#227;o respondedores a CsA&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; PCR alta&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mais frequente em respondedores &#224; CsA&#58; hist&#243;ria familiar positiva&#44; ASST positivo&#44; eosinopenia&#44; basopenia&#44; altos n&#237;veis de VHS&#44; n&#237;veis mais baixos de IgE total&#44; positividade para anti&#8208;TPO&#44; escores UCT basais mais baixos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Demonstra&#231;&#227;o de caracter&#237;sticas estatisticamente significantes e n&#227;o significantes por&#233;m mais frequentes&#44; observadas nos grupos de resposta ao tratamento da UCE</p>"
        ]
      ]
      4 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabela 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">anti&#8208;TPO&#44; anticorpo antitireoide peroxidase&#59; anti&#8208;TG&#44; anticorpo antitiroglobulina&#59; ASST&#44; teste cut&#226;neo de soro aut&#243;logo&#59; BAT&#44; teste de ativa&#231;&#227;o de bas&#243;filos&#59; BHRA&#44; ensaio de libera&#231;&#227;o de histamina de bas&#243;filos&#59; PCR&#44; prote&#237;na C reativa&#59; CsA&#44; ciclosporina&#8208;A&#59; UCE&#44; urtic&#225;ria cr&#244;nica espont&#226;nea&#59; VHS&#44; velocidade de hemossedimenta&#231;&#227;o&#59; <span class="elsevierStyleItalic">H&#46; pilori</span>&#44; <span class="elsevierStyleItalic">Helicobacter pylori</span>&#59; Oma&#44; omalizumabe&#59; UCT&#44; teste de controle de urtic&#225;ria&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:1 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">O que j&#225; se sabe sobre o tema&#63;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">O que este artigo acrescenta&#63;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A autoimunidade na UCE foi classificada em mecanismos autoimunes tipo 1 &#40;tipo IgE autoal&#233;rgico&#41; e mecanismos autoimunes tipo 2b &#40;tipo IgG&#41;&#46; Esses dois tipos t&#234;m sido associados a diferentes caracter&#237;sticas cl&#237;nicas e laboratoriais e padr&#245;es de resposta ao tratamento&#46; A urtic&#225;ria autoimune tipo 1 est&#225; associada a anticorpos IgE contra autoant&#237;genos&#44; taxas mais altas de doen&#231;as al&#233;rgicas concomitantes&#44; n&#237;veis de IgE total normais ou altos e altas taxas de resposta a omalizumabe&#46; A urtic&#225;ria autoimune tipo 2b est&#225; associada a anticorpos IgG contra autoant&#237;genos&#44; positividade para BHRA&#44; BAT&#44; ASST&#44; doen&#231;a mais grave com maior dura&#231;&#227;o&#44; maiores taxas de doen&#231;as autoimunes concomitantes&#44; maiores taxas de basopenia e eosinopenia&#44; n&#237;veis mais baixos de IgE total&#44; n&#237;veis mais altos de PCR&#44; positividade de ANA mais alta&#44; baixas taxas de resposta a anti&#8208;histam&#237;nicos e omalizumabe&#44; maiores taxas de resposta &#224; terapia imunossupressora&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Foram encontrados dois tipos distintos de end&#243;tipos de UCE de acordo com seus padr&#245;es de resposta ao tratamento que s&#227;o compat&#237;veis com os dois diferentes end&#243;tipos de urtic&#225;ria autoimune&#59; os respondedores ao Oma tendem a ser mais frequentemente do sexo masculino&#44; com atividade de doen&#231;a mais baixa &#40;escores UCT basais mais altos&#41; e com taxas mais baixas de positividade no ASST&#44; taxas mais baixas de hist&#243;ria familiar&#44; n&#237;veis mais baixos de PCR&#44; taxas mais baixas de basopenia e eosinopenia&#44; n&#237;veis mais baixos de VHS&#44; menor frequ&#234;ncia de angioedema&#44; menor frequ&#234;ncia de doen&#231;a autoimune da tireoide e n&#237;veis mais elevados de IgE total&#46; Estas s&#227;o caracter&#237;sticas que foram associadas &#224; autoimunidade tipo 1 &#40;tipo IgE&#41;&#46; Os respondedores &#224; CsA apresentaram n&#237;veis mais altos de PCR e maior frequ&#234;ncia de hist&#243;ria familiar positiva&#44; ASST positivo&#44; eosinopenia&#44; basopenia&#44; n&#237;veis mais altos de VHS&#44; maior frequ&#234;ncia de positividade anti&#8208;TPO&#44; n&#237;veis mais baixos de IgE total e maior atividade da doen&#231;a &#40;escores UCT basais mais baixos&#41;&#46; Estas s&#227;o caracter&#237;sticas que foram associadas &#224; autoimunidade tipo 2b &#40;tipo IgG&#41;&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Os biomarcadores para a resposta ao Oma foram relatados como altos n&#237;veis de IgE total&#44; negatividade no ASST&#44; negatividade no BHRA&#44; falta de atividade de up&#8208;regula&#231;&#227;o de bas&#243;filos CD203c&#44; alta express&#227;o de bas&#243;filos Fc&#603;RI e n&#237;veis mais baixos de IL&#8208;31&#44; enquanto biomarcadores para resposta &#224; ciclosporina foram relatados como positividade de BHRA&#44; n&#237;veis mais altos de PCR&#44; baixos n&#237;veis de IgE total&#44; positividade no ASST&#44; baixos n&#237;veis de d&#237;mero&#8208;D&#44; alta atividade da doen&#231;a e curta dura&#231;&#227;o da doen&#231;a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Os n&#227;o respondedores a nenhum dos dois medicamentos s&#227;o mais frequentemente do sexo feminino&#44; com maior atividade da doen&#231;a e com mais angioedema&#44; doen&#231;a autoimune da tireoide&#44; autoanticorpos da tireoide e positividade para <span class="elsevierStyleItalic">H&#46; pylori</span>&#46;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">O que j&#225; se sabe sobre o tema&#44; o que este artigo acrescenta&#63;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Refer&#234;ncias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:29 [
            0 => array:3 [
              "identificador" => "bib0150"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The EAACI&#47;GA&#40;2&#41;LEN&#47;EDF&#47;WAO guideline for the definition&#44; classification&#44; diagnosis and management of urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Zuberbier"
                            1 => "W&#46; Aberer"
                            2 => "R&#46; Asero"
                            3 => "A&#46;H&#46; Abdul Latiff"
                            4 => "D&#46; Baker"
                            5 => "B&#46; Ballmer-Weber"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13397"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2018"
                        "volumen" => "73"
                        "paginaInicial" => "1393"
                        "paginaFinal" => "1414"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29336054"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0155"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Looking forward to new targeted treatments for chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Kocaturk"
                            1 => "M&#46; Maurer"
                            2 => "M&#46; Metz"
                            3 => "C&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13601-016-0139-2"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Transl Allergy&#46;"
                        "fecha" => "2017"
                        "volumen" => "7"
                        "paginaInicial" => "1"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28078079"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0160"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Urticaria&#58; Collegium Internationale Allergologicum &#40;CIA&#41; Update 2020"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Maurer"
                            1 => "K&#46; Eyerich"
                            2 => "S&#46; Eyerich"
                            3 => "M&#46; Ferrer"
                            4 => "J&#46; Gutermuth"
                            5 => "K&#46; Hartmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000507218"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int Arch Allergy Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "181"
                        "paginaInicial" => "321"
                        "paginaFinal" => "333"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32224621"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0165"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutting Edge&#58; Biomarkers for Chronic Spontaneous Urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46; Folci"
                            1 => "E&#46; Heffler"
                            2 => "G&#46;W&#46; Canonica"
                            3 => "R&#46; Furlan"
                            4 => "E&#46; Brunetta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1155/2018/5615109"
                      "Revista" => array:5 [
                        "tituloSerie" => "J Immunol Res&#46;"
                        "fecha" => "2018"
                        "volumen" => "2018"
                        "paginaInicial" => "5615109"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30584542"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0170"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "IgE levels are negatively correlated with clinical response to ciclosporin in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46; Santiago"
                            1 => "B&#46; Ferreira"
                            2 => "L&#46; Ramos"
                            3 => "M&#46; Goncalo"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.17005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "180"
                        "paginaInicial" => "199"
                        "paginaFinal" => "200"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30007073"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0175"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors Predicting the Response to Cyclosporin Treatment in Patients With Chronic Spontaneous Urticaria&#58; A Systematic Review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Kulthanan"
                            1 => "C&#46; Subchookul"
                            2 => "S&#46; Hunnangkul"
                            3 => "L&#46; Chularojanamontri"
                            4 => "P&#46; Tuchinda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4168/aair.2019.11.5.736"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy Asthma Immunol Res&#46;"
                        "fecha" => "2019"
                        "volumen" => "11"
                        "paginaInicial" => "736"
                        "paginaFinal" => "755"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31332983"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0180"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Potential blood biomarkers in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "P&#46; Kolkhir"
                            1 => "F&#46; Andre"
                            2 => "M&#46;K&#46; Church"
                            3 => "M&#46; Maurer"
                            4 => "M&#46; Metz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cea.12870"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Allergy"
                        "fecha" => "2017"
                        "volumen" => "47"
                        "paginaInicial" => "19"
                        "paginaFinal" => "36"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27926978"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0185"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria&#58; Results of the PURIST Study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46; Schoepke"
                            1 => "R&#46; Asero"
                            2 => "A&#46; Ellrich"
                            3 => "M&#46; Ferrer"
                            4 => "A&#46; Gimenez-Arnau"
                            5 => "C&#46;E&#46;H&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13949"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy&#46;"
                        "fecha" => "2019"
                        "volumen" => "74"
                        "paginaInicial" => "2427"
                        "paginaFinal" => "2436"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31228881"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0190"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Randomized double&#8208;blind study of cyclosporin in chronic&#8217;idiopathic&#8217; urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "C&#46;E&#46; Grattan"
                            1 => "B&#46;F&#46; O&#8217;Donnell"
                            2 => "D&#46;M&#46; Francis"
                            3 => "N&#46; Niimi"
                            4 => "R&#46;J&#46; Barlow"
                            5 => "P&#46;T&#46; Seed"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1046/j.1365-2133.2000.03664.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2000"
                        "volumen" => "143"
                        "paginaInicial" => "365"
                        "paginaFinal" => "372"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10951147"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0195"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A positive serum basophil histamine release assay is a marker for ciclosporin&#8208;responsiveness in patients with chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "K&#46; Iqbal"
                            1 => "K&#46; Bhargava"
                            2 => "P&#46;S&#46; Skov"
                            3 => "S&#46; Falkencrone"
                            4 => "C&#46;E&#46; Grattan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/2045-7022-2-19"
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Transl Allergy&#46;"
                        "fecha" => "2012"
                        "volumen" => "2"
                        "paginaInicial" => "19"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23025508"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0200"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors that predict the success of cyclosporine treatment for chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46;M&#46; Hollander"
                            1 => "S&#46;S&#46; Joo"
                            2 => "H&#46;J&#46; Wedner"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2011.08.013"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma Immunol&#46;"
                        "fecha" => "2011"
                        "volumen" => "107"
                        "paginaInicial" => "523"
                        "paginaFinal" => "528"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22123382"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0205"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Response to oral cyclosporine therapy and high sensitivity&#8208;CRP level in chronic idiopathic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "T&#46; Ohtsuka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-4632.2010.04384.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Dermatol&#46;"
                        "fecha" => "2010"
                        "volumen" => "49"
                        "paginaInicial" => "579"
                        "paginaFinal" => "584"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20534097"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0210"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria&#58; Real&#8208;life data"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "A&#46; Salman"
                            1 => "G&#46; Demir"
                            2 => "N&#46; Bekiroglu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/dth.12975"
                      "Revista" => array:5 [
                        "tituloSerie" => "Dermatol Ther"
                        "fecha" => "2019"
                        "volumen" => "32"
                        "paginaInicial" => "e12975"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31145524"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0215"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "R&#46; Ertas"
                            1 => "K&#46; Ozyurt"
                            2 => "M&#46; Atasoy"
                            3 => "T&#46; Hawro"
                            4 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/all.13345"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy"
                        "fecha" => "2018"
                        "volumen" => "73"
                        "paginaInicial" => "705"
                        "paginaFinal" => "712"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29083482"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0220"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Serum IgE as an immunological marker to predict response to omalizumab treatment in symptomatic chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46;D&#46; Straesser"
                            1 => "E&#46; Oliver"
                            2 => "T&#46; Palacios"
                            3 => "T&#46; Kyin"
                            4 => "J&#46; Patrie"
                            5 => "L&#46; Borish"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2017.10.030"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2018"
                        "volumen" => "6"
                        "paginaInicial" => "1386"
                        "paginaFinal" => "1388"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29175369"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0225"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Factors related to omalizumab resistance in chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Magen"
                            1 => "T&#46; Chikovani"
                            2 => "D&#46;A&#46; Waitman"
                            3 => "N&#46;R&#46; Kahan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2500/aap.2019.40.4230"
                      "Revista" => array:6 [
                        "tituloSerie" => "Allergy Asthma Proc&#46;"
                        "fecha" => "2019"
                        "volumen" => "40"
                        "paginaInicial" => "273"
                        "paginaFinal" => "278"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31262381"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0230"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Basophil FcepsilonRI Expression in Chronic Spontaneous Urticaria&#58; A Potential Immunological Predictor of Response to Omalizumab Therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Deza"
                            1 => "M&#46; Bertolin-Colilla"
                            2 => "R&#46;M&#46; Pujol"
                            3 => "L&#46; Curto-Barredo"
                            4 => "D&#46; Soto"
                            5 => "M&#46; Garcia"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2340/00015555-2654"
                      "Revista" => array:6 [
                        "tituloSerie" => "Acta Derm Venereol&#46;"
                        "fecha" => "2017"
                        "volumen" => "97"
                        "paginaInicial" => "698"
                        "paginaFinal" => "704"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28303277"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0235"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Eosinopenia&#44; in Chronic Spontaneous Urticaria&#44; Is Associated with High Disease Activity&#44; Autoimmunity&#44; and Poor Response to Treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Kolkhir"
                            1 => "M&#46;K&#46; Church"
                            2 => "S&#46; Altrichter"
                            3 => "P&#46;S&#46; Skov"
                            4 => "T&#46; Hawro"
                            5 => "S&#46; Frischbutter"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2019.08.025"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "318"
                        "paginaFinal" => "325"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31472293"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0240"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cyclosporine and omalizumab together&#58; A new option for chronic refractory urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46; Sanchez"
                            1 => "L&#46; Alvarez"
                            2 => "R&#46; Cardona"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2020.02.012"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "2101"
                        "paginaFinal" => "2103"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32112923"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0245"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Concomitant treatment with omalizumab and cyclosporine for chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46;D&#46; Rosenblum"
                            1 => "S&#46; Nassau"
                            2 => "L&#46; Fonacier"
                            3 => "S&#46;L&#46; Mawhirt"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2020.04.020"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma&#46; Immunol"
                        "fecha" => "2020"
                        "volumen" => "125"
                        "paginaInicial" => "111"
                        "paginaFinal" => "112"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32360694"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0250"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Combination therapy with omalizumab and an immune&#8208;suppressive agent for resistant chronic spontaneous rrticaria &#8208; A real&#8208;life experience"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "R&#46; Maoz-Segal"
                            1 => "T&#46; Levy"
                            2 => "S&#46; Haj-Yahia"
                            3 => "I&#46; Offengenden"
                            4 => "M&#46; Iancovich-Kidon"
                            5 => "N&#46; Agmon-Levin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.waojou.2020.100448"
                      "Revista" => array:5 [
                        "tituloSerie" => "World Allergy Organ J&#46;"
                        "fecha" => "2020"
                        "volumen" => "13"
                        "paginaInicial" => "100448"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32774663"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0255"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Co&#8208;occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "R&#46; Asero"
                            1 => "A&#46;V&#46; Marzano"
                            2 => "S&#46; Ferrucci"
                            3 => "M&#46; Lorini"
                            4 => "V&#46; Carbonelli"
                            5 => "M&#46; Cugno"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/cei.13428"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Exp Immunol"
                        "fecha" => "2020"
                        "volumen" => "200"
                        "numero" => "3"
                        "paginaInicial" => "242"
                        "paginaFinal" => "249"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32115683"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0260"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Etiologic aspects and prognostic factors of patients with chronic urticaria&#58; nonrandomized&#44; prospective&#44; descriptive study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46; Gregoriou"
                            1 => "D&#46; Rigopoulos"
                            2 => "A&#46; Katsambas"
                            3 => "A&#46; Katsarou"
                            4 => "D&#46; Papaioannou"
                            5 => "A&#46; Gkouvi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2310/7750.2008.08035"
                      "Revista" => array:7 [
                        "tituloSerie" => "J Cutan Med Surg"
                        "fecha" => "2009"
                        "volumen" => "13"
                        "numero" => "4"
                        "paginaInicial" => "198"
                        "paginaFinal" => "203"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19706227"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0265"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "&#91;Epidemiologic features in patients with antihistamine&#8208;resistant chronic urticaria&#93;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "M&#46;S&#46; Borges"
                            1 => "S&#46; Tassinari"
                            2 => "A&#46; Flores"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Rev Alerg Mex&#46;"
                        "fecha" => "2015"
                        "volumen" => "62"
                        "paginaInicial" => "279"
                        "paginaFinal" => "286"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26556663"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0270"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Grieco"
                            1 => "L&#46; Dies"
                            2 => "A&#46; Sernicola"
                            3 => "C&#46; Chello"
                            4 => "N&#46; Gagliostro"
                            5 => "G&#46; Carnicelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2217/imt-2020-0088"
                      "Revista" => array:6 [
                        "tituloSerie" => "Immunotherapy&#46;"
                        "fecha" => "2020"
                        "volumen" => "12"
                        "paginaInicial" => "1173"
                        "paginaFinal" => "1181"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32892673"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0275"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Omalizumab Updosing for Better Disease Control in Chronic Spontaneous Urticaria Patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Kocaturk"
                            1 => "G&#46; Deza"
                            2 => "K&#46; Kiziltac"
                            3 => "A&#46;M&#46; Gimenez-Arnau"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000491530"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int Arch Allergy Immunol&#46;"
                        "fecha" => "2018"
                        "volumen" => "177"
                        "paginaInicial" => "360"
                        "paginaFinal" => "364"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30130798"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0280"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Urticaria and Angioedema Across the Ages"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Saini"
                            1 => "M&#46; Shams"
                            2 => "J&#46;A&#46; Bernstein"
                            3 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaip.2020.03.030"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Allergy Clin Immunol Pract&#46;"
                        "fecha" => "2020"
                        "volumen" => "8"
                        "paginaInicial" => "1866"
                        "paginaFinal" => "1874"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32298850"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0285"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Biomarkers In Chronic Spontaneous Urticaria&#58; Current Targets And Clinical Implications"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "I&#46; Puxeddu"
                            1 => "F&#46; Petrelli"
                            2 => "F&#46; Angelotti"
                            3 => "C&#46; Croia"
                            4 => "P&#46; Migliorini"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/JAA.S184986"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Asthma Allergy&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "285"
                        "paginaFinal" => "295"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31571935"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0290"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New treatments for chronic urticaria"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "P&#46; Kolkhir"
                            1 => "S&#46; Altrichter"
                            2 => "M&#46; Munoz"
                            3 => "T&#46; Hawro"
                            4 => "M&#46; Maurer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.anai.2019.08.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Allergy Asthma Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "124"
                        "paginaInicial" => "2"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31446134"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "pt"
  "url" => "/26662752/0000009700000005/v1_202209080628/S2666275222001849/v1_202209080628/pt/main.assets"
  "Apartado" => array:4 [
    "identificador" => "89618"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Artigo Original"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/26662752/0000009700000005/v1_202209080628/S2666275222001849/v1_202209080628/pt/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275222001849?idApp=UINPBA00008Z"
]
Informação do artigo
ISSN: 26662752
Idioma original: Português
Dados atualizados diariamente
Ano/Mês Html Pdf Total
2024 Novembro 32 9 41
2024 Outubro 228 95 323
2024 Setembro 294 119 413
2024 Agosto 288 136 424
2024 Julho 256 114 370
2024 Junho 237 76 313
2024 Maio 214 71 285
2024 Abril 229 97 326
2024 Março 314 76 390
2024 Fevereiro 196 81 277
2024 Janeiro 155 52 207
2023 Dezembro 149 57 206
2023 Novembro 157 73 230
2023 Outubro 114 73 187
2023 Setembro 191 106 297
2023 Agosto 186 37 223
2023 Julho 129 45 174
2023 Junho 114 47 161
2023 Maio 100 30 130
2023 Abril 82 26 108
2023 Março 139 49 188
2023 Fevereiro 92 29 121
2023 Janeiro 84 42 126
2022 Dezembro 136 38 174
2022 Novembro 136 68 204
2022 Outubro 139 79 218
2022 Setembro 107 90 197
2022 Agosto 31 38 69
Mostrar tudo

Siga este link para acessar o texto completo do artigo

Idiomas
Anais Brasileiros de Dermatologia (Portuguese)
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.